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ABSTRACT 
 Stimuli-responsive drug delivery materials release their payloads in response to 
physiological or external cues and are widely reported for stimuli such as pH, 
temperature, ionic strength, electrical potential, or applied magnetic field. While a 
handful of reports exist on materials responsive to mechanical stimuli, this area receives 
considerably less attention. This dissertation therefore explores three-dimensional 
networks and polymer-metal composites as mechanoresponsive biomaterials by using 
mechanical force to either trigger the release of entrapped agents or change the 
conformation of implants. 
At the nanoscale, shear is demonstrated as a mechanical stimulus for the release 
of a monoclonal antibody from nanofibrous, low molecular weight hydrogels formed 
from bio-inspired small molecule gelators. Using their self-healing, shear-thinning 
properties, mechanoresponsive neutralization of tumor necrosis factor alpha (TNFα) in a 
cell culture bioassay is achieved, suggesting utility for treating rheumatoid arthritis. 
Reaching the microscale, mechanical considerations are incorporated within the 
design of cisplatin-loaded meshes for sustained local drug delivery, which are fabricated 
through electrospinning a blend of polycaprolactone and poly(caprolactone-co-glycerol 
  viii 
monostearate). These meshes are compliant, amenable to stapling/suturing, and they 
exhibit bulk superhydrophobicity (i.e., extraordinary resistance to wetting), which 
sustains release of cisplatin >90 days in vitro and significantly delays tumor recurrence in 
an in vivo murine lung cancer resection model. This polymer chemistry/processing 
strategy is then generalized by applying it to the poly(lactide-co-glycolide) family of 
biomedical polymers. 
As a macroscopic approach, a tunable, tension-responsive multilayered drug 
delivery device is developed, which consists of a water-absorbent core flanked by two 
superhydrophobic microparticle coatings. Applied strain initiates coating fracture to 
cause core hydration and subsequent drug release, with rates dependent on strain 
magnitude. Finally, macroscopic, shape-changing polymer-composite materials are 
developed to improve the current functionality of breast biopsy markers. This shape 
change provides a means to prevent marker migration from its intended site—a current 
clinical problem. 
In summary, mechanoresponsive systems are described, ranging from the nano- to 
macroscopic scale, for applications in drug delivery and biomedical devices. These 
studies add to the nascent field of mechanoresponsive biomedical materials and the 
arsenal of drug delivery techniques required to combat cancer and other medical 
ailments.  
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CHAPTER 1:  Mechanoresponsive Materials & Their Applications as Drug 
Delivery Materials 
 
1.1 Overview 
 
Stimuli-responsive materials are well-suited for applications in drug delivery and 
work by releasing their drug payloads in response to either physiological or 
environmental (external) changes. This spatiotemporal control over drug release has been 
widely demonstrated for physiochemical stimuli such as pH,1-11 temperature,1,9,10,12-21 
ionic strength,22-24 electrical potential,25-32 and applied magnetic fields.33-43 While a 
handful of reports exist on drug delivery materials responsive to deformation and 
mechanical force (i.e., “mechanoresponsive” materials), this area has received 
considerably less attention. Yet, the human body is continuously subjected to micro- and 
macroscopic stresses and strains, and designing mechanoresponsive systems for 
biomedicine may be useful for a range of applications. This dissertation therefore focuses 
on three-dimensional networks and polymer-metal composite devices as 
mechanoresponsive biomaterials, which use mechanical force to either trigger the release 
of entrapped agents or change the conformation of a medical implant. This Chapter 
focuses on first introducing some intriguing and seminal reports within the broader field 
of mechanoresponsive materials, since these mechanoresponsive elements may find 
eventual use in drug delivery applications. Next, several notable reports on 
mechanoresponsive drug delivery are reviewed in order to establish the current state-of-
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the-art and stimulate further developments in this under-developed field of biomaterials 
research.  
 
1.2 Mechanoresponsive Materials with Potential Drug Delivery 
Applications 
 
One potential strategy for constructing mechanoresponsive drug delivery 
materials relies on the triggered wetting of normally non-wetting or slowly-wetting drug-
loaded materials. In this manner, water contact causes drug release and diffusion from 
within the device into the surrounding aqueous environment. Generally, approaches to 
mechanically induce the wetting of materials employs hydrophobic materials with 
microscopic structural features that become altered under tension. Without tension, these 
features render the material surface superhydrophobic, which is a surface property 
characterized by an advancing water contact angle greater than 150° and low contact 
angle hysteresis. Superhydrophobic surfaces are the result of the synergy between a low 
surface energy material and its rough topology, and applied tension destabilizes this 
architecture and promotes wetting through sagging of the liquid droplet at the material 
interface. 
Altering wettability through a mechanically-directed change in surface roughness 
was first reported by Lee, He, and Patankar in 2005 for applications in 
microelectromechanical systems (MEMS).44 Their approach first involved fabricating 
(via photolithography) rough poly(dimethylsiloxane) (PDMS) substrates consisting of 
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square pillars with 26-µm sides, heights of 25 µm, and inter-pillar spacings of 24 µm 
(Figure 1.1). This modification resulted in non-wetting surfaces (i.e., advancing contact 
angle ≈ 145°) approaching the superhydrophobic regime, whereas corresponding smooth 
films of PDMS possessed advancing water contact angles of ~115°. Next, a thin (< 2µm), 
smooth, conformal PDMS membrane was applied to the substrate using vacuum suction. 
In this manner, pneumatic actuation provided the deflection of the membrane from a 
smooth to rough geometry, thereby reversibly switching the degree of wettability (i.e., 
from a water contact angle of 115° to 145°) (Figure 1.2). 
Compared to the relatively modest changes in wettability (i.e., superhydrophobic 
to hydrophobic) described above, there have been several recent reports on using tension 
to induce the rapid wetting of materials (i.e., superhydrophobic to superhydrophilic). One 
noteworthy example was described by Choi, Tuteja, Chhatre, Mabry, Cohen, and 
McKinley,45 where simple cleanroom wipes were dip-coated with conformal coatings of 
fluorodecyl polyhedral oligomeric silsesquioxanes. The resulting materials were 
superomniphobic (i.e., non-wetting to water and oils alike), yet could be triggered to wet 
under a critical value of equibiaxial strain (Figure 1.3). As expected, their observation of 
critical strain values (ε ≈ 0.2-0.6) at which wetting occurred varied depending on the 
probing liquid surface tension, with hexadecane commanding the highest critical strain 
value and octane the lowest (Figure 1.4). Accompanying these studies was a 
mathematical analysis of the surface morphology, which explained the geometric factors 
responsible for droplet sagging and wetting. From these considerations, and from data 
presented in their prior reports on designing superoleophobic surfaces,46 they constructed 
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a mathematical model to describe a set of topographical parameters required for wetting 
under equibiaxial strain, such as critical spacing ratio, robustness factor, and reentrant 
curvature. 
Without any surface treatments or modifications, Zhang, Lu, Huang, and Han47 
provided another example of wetting in response to equibiaxial tension, this time using a 
triangular net-shaped polyamide mesh consisting of 20-µm diameter fibers. In this case, 
the mesh was presumably superhydrophobic (not superomniphobic), with the 200-µm 
pores providing a rough surface with spacing appropriate to support a water droplet with 
an advancing contact angle of 151° (Figure 1.5). Under equibiaxial strain of 
approximately 120%, the pores expanded to 450 µm (Figure 1.6), resulting in droplet 
sagging and subsequent wetting. This non-wetting to wetting transition is reversible 
through several cycles of elongation and relaxation due to the elastomeric nature of the 
material. 
These two reports of using tension to transition from a superhydrophobic to 
superhydrophilic (wetting) state are useful for practical applications as well as theoretical 
guidelines for the further development of tension-responsive, non-wetting materials. 
However, despite a thorough description of their systems, both groups excluded mention 
of applications for such a technology. Given that superhydrophobic materials were only 
recently reported for drug delivery applications, their use as mechanoresponsive drug 
delivery depots warrant additional study. Accordingly, we detail a mechanoresponsive 
drug delivery system constructed from superhydrophobic materials later in this work 
(Chapter 5). 
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1.3 Mechanoresponsive Drug Delivery Materials 
 
There are only a few reported mechanoresponsive drug delivery systems at the 
time of this writing, yet the reports that do exist cover the breadth of mechanical forces: 
compression, tension, and shear. Ultrasound may also be considered a mechanical 
stimulus. However, since much of the attractiveness of mechanoresponsive drug delivery 
is due to the ease of applying tensile, compressive, and shear stimuli, and to the ubiquity 
of these forces in the human body, a review of ultrasound-mediated drug delivery is 
omitted here. In addition, several recent reviews have been published on ultrasound-
triggered drug delivery,48-62 making its review in this dissertation unnecessary. The 
following review is therefore grouped according to the respective forces used for 
mechanical stimulation of drug release. 
 
1.3.1 Compression-Responsive Drug Delivery Materials 
The earliest report on mechanoresponsive drug delivery comes from Lee, Peters, 
Anderson, and Mooney and their work on compression-triggered release of growth 
factors from alginate hydrogels for promoting neovascularization.63,64 Their system relied 
on the reversible binding of vascular endothelial growth factor (VEGF) to the alginate 
matrix, as they noted that compression of gels loaded with trypan blue did not exhibit a 
significant difference in cumulative release compared to gels not subjected to 
compression. Using 25% compressive strain, the VEGF release rate increased five-fold 
over the first 10 minutes, and intermediate rates were achieved by adjusting the strain 
magnitude to 10% (Figure 1.7). They explained that the increased release of VEGF 
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under compression was due to the exudation of free (i.e, not bound) VEGF within the 
matrix. Relaxation of the matrix then permitted re-equilibration of bound and unbound 
VEGF, allowing its cyclical release with each compressive cycle. Using this system, 
cumulative release of VEGF from cyclically-compressed hydrogels was twice that of 
uncompressed gels (Figure 1.8). Lastly, the authors demonstrated efficacy of this system 
in vivo by implanting VEGF-loaded hydrogels in severe combined immunodeficient 
(SCID) mice, and non-obese diabetic mice in a separate experiment, and subjected the 
mice/implants to mechanical stimulation. Compared to non-stimulated VEGF-loaded 
gels, tissue sections from mice undergoing mechanical stimulation showed a statistically 
significant increase in vascularization, which was determined from the thickness of the 
surrounding granulation tissue and number of surrounding blood vessels. 
Izawa, Kawakami, Sumita, Tateyama, Hill, and Ariga reported another example 
of compression-responsive implantable hydrogels by utilizing the host-guest principles of 
drug--cyclodextrin complexes (Figure 1.9).65 Specifically, these authors demonstrated 
the mechanoresponsive release of ondansetron (ODN), an anti-emetic drug used to reduce 
chemotherapy-induced nausea and vomiting, from alginate hydrogels crosslinked with a 
-cyclodextrin derivative in order to provide on-demand patient control over dosage. 
Because of the non-covalent association of drugs with -cyclodextrins via van der Waals 
and hydrophobic interactions, mechanical disruption of the -cyclodextrin moiety can 
dramatically alter their affinity to drugs. To test their system, the authors applied either a 
single compression (30% or 50% strain for 5 minutes), or five compression cycles (30% 
or 50% strain for 5 minutes) followed by 5 minutes relaxation, on ODN-loaded 
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hydrogels, while monitoring ODN release. The authors noted the accelerated release of 
ODN from compressed samples compared to those under static conditions (Figure 1.10). 
An additional experiment that further emphasizes the role of crosslinked -cyclodextrin 
involved constructing alginate hydrogels with -cyclodextrin grafted onto the algninate 
backbone. These non-crosslinked hydrogels failed to release ODN in a 
mechanoresponsive fashion (Figure 1.11), and confirms that the deformation of -
cyclodextrin, through its cross-connectivity with the alginate matrix, is required for 
mechanoresponsive release, rather than a simple “squeezing-out” effect by water 
exudation. UV-Vis spectroscopy also confirmed the change in host-guest association 
under 50% strain, where the absorption maximum of ODN, initially at 303 nm within the 
inclusion complex, shifts to 307 nm under deformation; free ODN has a maximum 
absorption coefficient in aqueous solution at 312 nm. 
Another example of a hydrogel responsive to cyclical compression was reported 
by Yang, Tang, Zhang, Zhao, Yuan, Fan, and Wang, which demonstrated the controlled 
release of bovine serum albumin (BSA) from porous poly(lactide-co-glycolide) (PLGA)-
based matrices.66 In this study, BSA-loaded microspheres were incorporated within the 
scaffold with the block copolymer poly(ethylene glycol)-b-poly(L-lactide) (PELA) using 
a double-emulsion technique. The resulting cylindrical scaffolds were cyclically 
compressed (1 Hz) for 3 hours each day, and incubated in a shaking water bath for the 
remaining duration (Figure 1.12). In contrast, BSA-loaded control scaffolds were 
incubated in shaking water baths without cyclical loading. The release supernatants were 
periodically assessed for BSA concentration, and the authors reported that cyclic loading 
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accelerated BSA release compared to static scaffolds. However, this report had several 
limitations, particularly the high degree of burst release experienced in both static and 
compressed samples and a relatively minor difference in cumulative release profiles 
between the two (Figure 1.13). There is also no indication that the observed differences 
would elicit any significant difference in performance in vitro or in vivo, and the authors 
did not provide a bioassay to indicate otherwise.  
The final compression-responsive drug delivery system reviewed here is a 
hyaluronic acid (HA)-based hydrogel containing covalently integrated soft and 
deformable dexamethasone (DEX) depots, reported by Xiao, Tong, Chen, Pochan, 
Sabanayagam, and Jia.67 DEX is a steroid medication used for suppressing a variety of 
inflammatory and autoimmune conditions. This particular hydrogel system consists of 
block copolymer micelles (BCM) composed of poly(acrylic acid-graft-2-hydroxyethyl 
acrylate)-block-poly(n-butyl acrylate) tethered to glycidyl methacrylate-modified HA 
using photo-initiated free-radical polymerization (Figure 1.14). Owing to its 
lipophilicity, DEX was sequestered within the hydrophobic BCM cores, yet could be 
released in an on-demand fashion through the application of compression. For example, 
DEX release was approximately 6 µg/h under static conditions, but increased to 345 µg/h 
when subjected to 1 hour of 30% compressive strain, which represented 37% of the total 
drug payload. In addition, DEX release rate depended on the magnitude of compressive 
strain, with 15% strain resulting in a 1.6× slower release rate. Over 8 hours, the 
cumulative release of DEX from these hydrogels subjected to 0, 15, and 30% 
compressive strain was approximately 5, 40, and 60%, respectively (Figure 1.15). 
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However, the authors note that an initial 3-hour washout period was required to achieve 
mechanoresponsive release of DEX, due to burst release being the primary mode of drug 
release during this duration. Lastly, the authors applied this hydrogel system to an in vitro 
model of inflammation using RAW264.7 macrophages, where they demonstrated a 
statistically significant reduction in levels of secreted tumor necrosis factor alpha (and 
thus a reduction in macrophage activation) after stimulation by lipopolysaccharides. 
However, the authors did not use mechanically-stimulated hydrogels for this study, citing 
technical challenges, and therefore only comment on the efficacy of DEX delivery under 
static conditions. Owing to their observed burst release kinetics described earlier, these in 
vitro results are not particularly surprising, and it has yet to be shown whether the 
mechanoresponsive aspect of their system confers any advantage over statically-cultured 
hydrogels, although the authors mention their ongoing efforts translating this work to an 
in vivo study involving mice with osteoarthritis (OA)-like symptoms. Interestingly, the 
authors did not describe any attempt to release DEX under tension despite their reports of 
the hydrogel’s elastomeric properties. This may be due to their interests in applying this 
system to the treatment of OA and cartilage degeneration, where compression is the 
primary mechanical force encountered. The authors do, however, report on a similar 
mechanoresponsive hydrogel system that employs tension as the drug release stimulus, 
which is discussed later in this Chapter. 
 
 
 
 
10 
1.3.2 Tension-Responsive Drug Delivery Materials 
In contrast to compressive forces encountered in cartilage and bone, muscle and 
tendons routinely experience tension, representing a biomaterials area for which tension-
responsive drug delivery features may be useful.  Hyun, Moon, Park, Kim, Xia, and 
Jeong first reported a tension-responsive drug delivery system involving arrayed 
microcapsules supported on an elastomeric substrate—specifically, a thin film of 
polystyrene (PS) supported on a poly(dimethylsiloxane) (PDMS) substrate (Figure 
1.16).68 These PS films were processed through thermal cycling to afford isotropic, 
buckled structures, which were loaded with either fluorescein-isothiocyanate (FITC)-
labeled dextran (MW = 10,000 g/mol) or rhodamine B—both serving as model drugs—
using a dip-coating process. The final drug delivery device consisted of sealed 
microcapsules, achieved by affixing the buckled PS film to a soft PDMS substrate. The 
authors studied the morphological changes of the microcapsules in response to tensile 
strain using atomic force microscopy (AFM), with experimental results closely agreeing 
with theoretical predictions of their height and spacing variations under dynamic 
stretching. These devices could tolerate a maximum strain of ~7.5% before the fracture of 
the PS film occurred, and the authors demonstrated that release of rhodamine B could be 
controlled by repeated stretching of these devices, with the amount dependent on strain 
magnitude. FITC-dextran-loaded devices, however, did not release from these devices 
under both static and dynamic conditions, which the authors attributed to its 
macromolecular nature (Figure 1.17). That is, this mechanoresponsive system required 
the diffusion of molecules through the PS membrane, which was possible for a small 
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molecule such as rhodamine B, but severely restricted for a macromolecule such as 
FITC-dextran. Therefore, this system is limited to small molecule drug delivery, and 
leaves room for improvement in mechanoresponsive drug delivery systems that are 
capable of delivering both small and macromolecular therapies. 
In contrast to the above report, which was limited to the study of relatively low 
magnitude tensile strains to prevent fracture of the polymeric films, the research groups 
of Lavalle and Schaaf reported a tension-responsive delivery system that was capable of 
experiencing strain values up to 100% and initiated drug release through either: 1) 
enzymatic modification of entrapped model prodrugs;69 or 2) enzymatic degradation of 
their polymeric substrata.70  
The first study, performed by Vogt, Mertz, Benmlih, Hemmerlé, Voegel, Schaaf, 
and Lavalle, involved two strata of polyelectrolyte multilayers supported on an 
elastomeric PDMS sheet.69 The two strata consisted of a thick, hydrated poly(L-
lysine)/hyaluronic acid (PLL/HA) film acting as a drug (i.e., fluorescein diphosphate, 
FDP) reservoir and a thin (90 nm) capping layer composed of 10 sequential bilayers of 
poly(diallyldimethylammonium)/poly(sodium-4-styrenesulfonate) (PDADMA/PSS)10. 
The enzyme alkaline phosphatase (ALP), which dephosphorylates non-fluorescent FDP 
to yield fluorescently-active fluorescein (F), was then adsorbed on a final PDAMA/PSS 
layer. In the absence of tension, the PDADMA/PSS10 stratum served as an effective 
barrier to the diffusion of FDP and therefore isolated it from the enzyme present on the 
device surface. However, when tensile strains above a critical threshold of 60% were 
applied to these materials, nano-/microscopic structural reorganization occurred within 
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the PDADMA/PSS10 barriers, leading to a change in their permeability and permitting 
diffusion of FDP through the barriers. Consequently, adsorbed ALP could bind these 
freely diffusing FDP molecules, leading to a dramatic increase in fluorescence intensity 
(Figure 1.18). Despite this study involving only a model drug, which precluded it from a 
specific biological application, the authors suggest that this system may be applied to the 
release of prodrugs that may require enzymatic action to achieve their final bioactive 
formulation. 
While the above study demonstrated the principle of chemical and enzymatic 
modification for stretch-induced reactive release of a model prodrug, Barthes, Mertz, 
Bach, Metz-Boutigue, Senger, Voegel, Schaaf, and Lavalle subsequently applied their 
polyelectrolyte multilayer system to the enzymatic degradation of drug-loaded polymeric 
films.70 In this case, the mechanosensitive barrier layer consisted of 
poly(allylamine)/poly(styrene sulfonate) (PAH/PSS), while the reservoir layer consisted 
of PLL/HA—identical to their prior report. The authors used trypsin (TRY), a protease 
that recognizes and acts on the C-terminus of lysine residues present in polypeptide 
chains, to cause the enzymatic degradation of the PLL-based reservoir, which contained 
paclitaxel, a potent mitotic inhibitor chemotherapeutic agent (Figure 1.19). Without 
applied tension, the PAH/PSS barrier isolated the reservoir from trypsin’s action and 
prevented drug release. However, mechanical extension to a strain of 30% fractured the 
barrier, permitting TRY diffusion into the reservoir through these cracks and causing its 
degradation and release of paclitaxel. Over 8 hours and in the presence of TRY, the 
authors were able to achieve a 7-fold increase in fluorescently-labeled paclitaxel release 
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using 30% tensile strain compared to non-stretched devices and devices stretched to 
100% strain in the absence of TRY, confirming the necessity of both stretch and 
enzymatic activity for drug release (Figure 1.20). It is worth noting that in this study, the 
authors specifically described (and showed via microscopy) the formation of microscopic 
fractures within the barrier layer as the initiating mechanism for drug release, yet this was 
not the case for their previous study, for which a thorough mechanistic evaluation was 
lacking. 
While the majority of tension-responsive drug delivery systems involve polymer-
based films (many of which rely on an underlying PDMS substrate), Xiao, Zhu, 
Londono, Pochan, and Jia demonstrated the ability to employ elastomeric hydrogels for 
the mechanoresponsive release of pyrene, a model drug.71 The authors first prepared ~20 
nm block copolymer micelles (BCM) from amphiphilic di-block copolymers consisting 
of poly(n-butyl acrylate), the hydrophobic portion, and poly(acrylic acid) modified with 
20 mol% 2-hydroxyethyl acrylate, which served as both the hydrophilic portion and 
moiety responsible for free radical crosslinking within the bulk hydrogel. The BCMs 
were then loaded with pyrene with high efficiency (~99%) and copolymerized with 
acrylamide (AAm) to yield BCM-crosslinked pAAm elastomeric hydrogels, which were 
capable of reversible extension/relaxation under strains approaching 350%. By 
crosslinking BCM within the hydrogel, stretched hydrogels transferred this macroscopic 
deflection to BCM crosslinks, causing their morphological changes that favored pyrene 
release (Figure 1.21). Mechanical stimulation, followed by relaxation, of these hydrogels 
was performed in 5-minute intervals for 1 hour (4 mm/s, 0.2 Hz), with strains of either 
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30% or 60% strain. As expected, hydrogels stretched at 60% strain released pyrene at a 
faster rate over the first extension/relaxation interval than hydrogels stretched to 30% and 
those incubated under static conditions (0.54 ng/min versus 0.19 and ~0.08 ng/min, 
respectively). In addition, cumulative release of pyrene over 60 minutes was greatest for 
gels stretched to 60%, compared to those stretched to 30% and non-stretched samples 
(25%  versus 15% and 10%, respectively) (Figure 1.22). Despite their ability to achieve 
reversible extensions up to 350% strain, the authors limited their pyrene release study to a 
maximum strain value of 60% without providing a rationale for this decision. 
Considering only 25% of the pyrene payload was released, the question remains as to 
whether greater strains or a longer incubation duration could release a greater percentage 
of pyrene. 
 
1.3.3 Shear-Responsive Drug Delivery Materials 
 Drug delivery materials focused on the shear-mediated release of entrapped 
agents have so far been limited to the circulatory system, where fluid flow acts on blood 
vessel lamina. In particular, points of occlusion or thrombosis present a stimulus of 
increased shear force, as the narrowing of vessels at these junctures causes a dramatic 
increase in shear stress. These applications call for nanoparticle-based therapies, and have 
been achieved using phospholipid vesicles and solid polymeric nanoparticles, loaded with 
either 5(6)-carboxyfluorescein (as a model drug) or tissue plasminogen activator, 
respectively. 
The first example of using shear to release entrapped agents was reported by 
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Holme, Fedotenko, Abegg, Althaus, Babel, Favarger, Reiter, Tanasescu, Zaffalon, 
Ziegler, Müller, Saxer, and Zumbuehl,72 and involved 1,3-diamidophospholipid-based 
vesicles having lenticular, rather than spherical, morphologies. While the authors argued 
that spherical vesicles are robust and resistant to mechanical disruption, they cited 
computational studies suggesting that altered morphologies generated by the large 
bending moduli of modified phospholipid membranes presented the opportunity for 
disassembly upon elevated shear stress due to breakage along their equators. The authors 
prepared large, unilamellar vesicles by extrusion (LUVET), which were composed of 
synthetic 1,3-dipalmitamidopropan-2-yl 2-(trimethylammonio)ethyl phosphate lipids 
(Pad–PC–Pad). The amide groups were critical for imparting shear sensitivity, 
presumably due to the alignment of the amide functional groups through hydrogen 
bonding. Next, the authors applied this system to an in vitro model of atherosclerosis 
using simulated healthy (shear stress = 2 Pa) and severely constricted arteries (shear 
stress = 40 Pa) constructed from poly(methyl methacrylate) (Figure 1.23). The inlet of 
both arteries were 2.5 mm in diameter, while the constricted arteries had their diameter 
reduced to up to 75% along a 2.5-cm segment. Flow was generated using an 
extracorporeal pump operating with pressures, flow rates, osmolarity, and temperature 
within physiologically-relevant ranges. After 40 passes of Pad-PC-Pad through their 
system, shear-responsive vesicles released 70% of entrapped dye when passing through 
the constricted artery model compared to only 45% of dye when passed through healthy 
arteries (Figure 1.24). Because the authors focused their efforts on the design and 
optimization of phospholipid vesicles to achieve shear-responsive release, the report was 
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limited to in vitro studies using a fluorescent dye as a model drug, and left open the 
opportunity to demonstrate in vivo efficacy in a clinically-relevant model with 
pharmacologically active agents. 
Indeed, Korin, Kanapathipillai, Matthews, Crescente, Brill, Mammoto, Ghosh, 
Jurek, Bencherif, Bhatta, Coskun, Feldman, Wagner, and Ingber73 applied shear-
responsive drug delivery to a similar model of elevated shear stress in cardiovascular 
disease (Figure 1.25), and extended their study to an in vivo murine model of myocardial 
infarction and pulmonary embolism. In this study, the authors fabricated nanoparticle 
microaggregates composed of the biocompatible, biodegradable copolymer poly(lactide-
co-glycolide) (50:50, 17 kDa) via spray-drying. These aggregates mimicked the size of 
platelets (1 to 5 µm) and were stable under shear stresses commonly experienced by non-
obstructed coronary vessels (10 – 30 dyne/cm2), yet could be triggered to break apart 
upon experiencing pathologically-relevant shear stresses (> 100 dyne/cm2). The authors 
first evaluated their fluorescently-tagged nanoparticle aggregates’ efficacy in a three-
dimensional microfluidic device, fabricated from PDMS, which contained a 90% luminal 
narrowing to simulate a clot. They noted a 16-fold increase in fluorescence downstream 
of the narrowing (due to de-quenching of the fluorophores), compared to that from 
particles flowing throughout devices without luminal obstruction, and also noted a 
marked increase in intracellular fluorescence in endothelial cells distally cultured to the 
obstructed lumen. Finally, these nanotherapeutics were coated with the thrombolytic drug 
tissue plasminogen activator (tPA) using biotin-streptavidin chemistry, and evaluated for 
thrombolytic efficacy in a mouse arterial thrombus model. Using their shear-activated 
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nanotherapeutics, the authors were able to achieve superior performance in restoring 
pulmonary arterial pressure with a 100-fold lower effective dose of tPA (Figure 1.26). 
 
1.4 Conclusion & Future Directions 
 
The field of mechanoresponsive drug delivery is still developing, yet the reports 
that do exist demonstrate the promise of using a battery of drug delivery platforms 
(hydrogels and nanoparticles, for example) to achieve mechanoresponsive release of 
pharmaceutical agents. While alginate hydrogels were shown useful for compression-
based drug delivery, there has been an increasing interest in low molecular weight 
hydrogels to afford faster clearance from the body. Additionally, mechanoresponsive 
hydrogels have mostly been investigated for compression and not yet for the shear-
mediated release of macromolecules. Furthermore, the reports of tension induced wetting 
provide a possible mechanism for drug release, by having water infiltration cause the 
release of agents entrapped within the network. Finally, many of the mechanoresponsive 
drug delivery reports so far have struggled to prevent burst release in the absence of 
stimuli. Therefore, the goal of this dissertation work is to develop mechanoresponsive 
systems that improve upon these current reports using novel materials and mechanisms of 
drug release.  
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Figure 1.1 (A) Profile view of PDMS device consisting of pillars (white arrow) 
covered by a thin membrane (black arrow). (B) Pneumatic actuation (i.e., vacuum 
suction) causes the membrane film to deflect downward, enhancing the substrate 
roughness and generating higher water contact angles approaching the superhydrophobic 
regime (H = 25 µm, a = 26 µm, b = 24 µm; θs = 135° and is the inclination angle of the 
roughness feature).44  
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Figure 1.2 Water contact angles (A) upon pneumatic actuation, where the PDMS 
membrane is deflected downward to reveal PDMS pillar features and generate a 
superhydrophobic surface, and (B) upon removal of actuation, allowing the PDMS 
membrane to relax and cover the pillar features to increase wettability.44  
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Figure 1.3 (A) Advancing (red open squares) and receding (closed blue circles) 
contact angles of dodecane droplets on superomniphobic polyester fabrics as a function 
of increasing equibiaxial strain. Dashed lines represent mathematical predictions of 
contact angle. (B) Advancing contact angle of decane droplets on superomniphobic 
polyester fabrics, showing non-wetting (~150°) without stretch (red circles), and 
subsequent wetting with 30% strain (blue squares, advancing contact angle = 0°). The 
superomniphobic properties return upon the release of strain and is repeated over 5 
cycles.45  
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Figure 1.4 Superomniphobic polyester fabrics with tunable wettability as a function 
of increasing equibiaxial strain. (A) Unstretched fabrics support droplets of (starting at 
top left, moving counterclockwise) octane, decane, dodecane, and hexadecane. These 
liquids have surface tensions of 21.7, 23.8, 25.3, and 27.8 mN/m, respectively. (B) 
Wetting of superomniphobic polyester fabric with octane at 15% biaxial strain. (C) 
Decane wetting at 30% strain. (D) Dodecane wetting at 60% strain. Hexadecane wets at 
the point of fabric tearing (~70%). The value of D* corresponds to a dimensionless 
parameter describing geometric spacing between surface features.45  
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Figure 1.5 (A) Water contact angle measurements on an elastic polyamide mesh 
possessing triangular pores before (left) and after equibiaxial stretch of ~120% (right), 
which causes wetting. (B) Altering wettability from non-wetting to wetting is achieved 
over >10 cycles.47   
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Figure 1.6 Scanning electron micrographs showing the microscale features of an 
elastic polyamide mesh with triangular pores (A) before applying tension, with average 
pore side length of 200 µm. Inset shows individual fibers of ~20 µm diameter. (B) After 
equibiaxial strain of 120%, average pore side length increases to 450 µm. Scale bar = 500 
µm.47  
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Figure 1.7 (A) Schematic diagram of the application of 6 cycles of compression to 
VEGF-loaded alginate hydrogels (on = compression for 2 minutes, off = relaxation for 8 
minutes). (B) Release rates of VEGF from hydrogels at rest (closed circles) or subjected 
to compressive strains of 10% (open circles) or 25% (open squares).63  
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Figure 1.8 Cumulative release of VEGF from alginate hydrogels at rest (closed 
circles) or subjected to 10% (open circles) or 25% (open squares) compressive strain.63  
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Figure 1.9 Schematic diagram of compression-responsive alginate hydrogels (green 
fibers) functionalized with -cyclodextrin moieties (yellow cups). (A) Hydrogels with 
interfiber crosslinking by -cyclodextrin alters the cyclodextrin morphology (CCAL), 
whereas (B) non-crosslinked hydrogels with pendant -cyclodextrins (CGAL) lack this 
morphological change upon compression.65  
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Figure 1.10 Percent release of ondansetron (ODN) from -cyclodextrin crosslinked 
alginate hydrogels (CCAL) at rest (blue squares) or subjected to 30% or 50% strain 
(orange triangles or red diamonds, respectively). Purple and red arrows correspond to 
single or five-cycle compression cycles, respectively.65  
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Figure 1.11 Percent release of ODN from pendant (non-crosslinked) -cyclodextrin-
modified alginate hydrogels, showing a lack of mechanoresponsive release behavior.65  
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Figure 1.12 (A) Schematic diagram of the release of BSA from PELA microspheres 
using water diffusion as a release stimulus. (B) Static release of BSA from PELA 
microspheres entrapped within PLGA cylindrical scaffolds. (C) Mechanoresponsive 
release of BSA from microspheres using compression to increase water permeation.66  
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Figure 1.13 Percent release of BSA from PELA microspheres only (black squares), or 
from microspheres encapsulated within PLGA scaffolds under static conditions or cyclic 
compressive loading (triangles and circles, respectively).66  
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Figure 1.14 Schematic diagram of compression-responsive hyaluronic acid-based 
hydrogels containing dexamethasone (DEX)-loaded (red) block copolymer micelle 
(blue/green) crosslinks (xBCM(DEX)). (A) Incorporation of xBCM(DEX) within 
glycidyl methacrylated hyaluronic acid (HAGMA) using UV irradiation. (B) 
Compression distorts the block copolymer micelles, which lose affinity for DEX and 
cause its release into the aqueous environment.67  
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Figure 1.15 (A) Compression-responsive release of dexamethasone (DEX) from 
glycidyl methacrylate-modified hyaluronic acid (HAGMA) hydrogels containing block 
copolymer micelle (BCM) crosslinks using 15% (red circles) or 30% (black squares) 
compressive strain for 1 hour, followed by 1 hour rest. The release of samples under 
static conditions are shown as blue triangles. (B) Hydrogels lacking covalent crosslinking 
integration of BCMs lack mechanoresponsive DEX release behavior.67  
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Figure 1.16 (A) Scanning electron micrograph (SEM, top view) of tension-responsive 
arrayed polystyrene microcapsules (PS) on PDMS substrates. (B) Optical fluorescence 
micrograph of arrayed microcapsules loaded with rhodamine B. (C) SEM side view 
showing the profile of arrayed microcapsules (inset: high magnification of capsule, scale 
bar = 2 µm).68  
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Figure 1.17 Tension-responsive release of arrayed microcapsules containing entrapped 
FITC-dextran (MW = 10,000 g/mol) (“1”) and rhodamine B (“2”) as a function of strain. 
Arrows indicate the point of stress application, which was identical for each curve. Note: 
fluorescence intensity decreases because the authors were measuring the intensity of the 
arrayed microcapsule device, not the intensity of the release sink.68  
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Figure 1.18 (A) Schematic diagram of tension-induced enzymatic conversion of non-
fluorescent fluorescein diphosphate (FDP) to fluorescent fluorescein. Alkaline 
phosphatase (ALP) was embedded in a polyelectrolyte barrier layer of 
(PDADMA/PSS)10. Tension allows FDP to diffuse from within PLL/HA films through 
the barrier pores to the device surface, where it is converted to fluorescein. (B) 
Fluorescence intensity of buffer solution as the device is subjected to increasing strain.69  
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Figure 1.19 Stretch-induced enzymatic degradation of layer-by-layer films. (A) 
Poly(L-lysine)/hyaluronic acid multilayered films are protected from degradation by 
trypsin (present in the buffer solution) due to the presence of a mechanosensitive 
polyallylamine/poly(styrene sulfonate) barrier. (B) Tension causes crack development in 
the barrier, allowing trypsin to degrade the film and release entrapped paclitaxel.70  
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Figure 1.20 Release of entrapped fluorescently-tagged paclitaxel under 30% strain 
(diamonds) from mechanoresponsive polyelectrolyte multilayered films, as measured by 
fluorescence intensity. Devices not subjected to tension (triangles) do not release 
paclitaxel. Devices subjected to stretch, but without trypsin present, also do not release 
paclitaxel.70  
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Figure 1.21 (A) Cross-sectional transmission electron micrographs (TEM) of 
polyacrylamide hydrogels containing crosslinked block copolymer micelles in the 
unstretched (left) and stretched state (right). (B) Schematic illustration of micelle 
distortion under tension.71  
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Figure 1.22 (A) Release rate of pyrene from tension-responsive hydrogels using 0%, 
30%, and 60% tensile strain (purple squares, blue circles, and black triangles, 
respectively). (B) Cumulative release of pyrene under 0%, 30%, and 60% tensile strain 
(purple squares, blue circles, and black triangles, respectively).71  
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Figure 1.23 (A) Schematic diagram of a plaque formation in a blood vessel, which 
causes an increase in shear stress to deform vesicles and trigger drug release. (B) 
Experimental model used for studying shear stress-responsive drug release from 
lenticular vesicles in healthy (top) and constricted (middle and bottom) microfluidic 
devices.72  
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Figure 1.24 (A) Percent release of carboxyfluorescein from shear-responsive lenticular 
vesicles as a function of Pad-PC-Pad and vessel occlusion (i.e., shear stress). (B) 
Difference in percent release of carboxyfluorescein from vesicles as a function of Pad-
PC-Pad.72  
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Figure 1.25 (A) Schematic illustration of plaque formation and clot dissolution using 
shear-activated nanotherapeutics. (B) tPA-loaded microparticles (consisting of 
nanoparticle aggregates) break up into nanoparticles upon experiencing increased shear 
forces at the clot, where they adhere. (C) Thrombolysis, trough the pharmacological 
activity of tPA, restores blood flow.73  
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Figure 1.26 (A) Nanoparticle concentration as a function of shear stress exerted on 
microparticle aggregates, showing their break-up under pathologically-relevant shear 
stresses. (B) Restoration of pulmonary artery pressure in an ex vivo mouse model of 
pulmonary embolism, showing the superior efficacy (i.e., 100-fold lower required dose of 
tPA) of shear-activated nanotherapeutics, compared to free tPA.73 
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CHAPTER 2:  Low Molecular Weight Hydrogels as Shear-Responsive 
Biopharmaceutical Drug Delivery Depots 
 
 
2.1 Introduction 
 
Hydrogels are of interest across a broad range of biomedical activities including 
drug delivery, high throughput screening, tissue engineering, and wound-healing.74-85 
Traditionally, hydrogels are prepared from large molecular weight macromolecules 
(>5,000 g/mol) via physical entanglements or chemical crosslinking of the constituents.  
More recently, the principles of supramolecular chemistry86 are being exploited to 
prepare small molecules that self-assemble into higher-order functional structures, 
affording hydrogels,87-91 including those that are stimuli-responsive92,93 and/or self-
healing.94,95 Often the low molecular weight (LMW) gelators used to form these 
supramolecular systems possess biologically important chemical structures including 
peptides,91,96,97 carbohydrates,98 or nucleosides.99,100 
From a biomedical applications viewpoint, LMW gelators that spontaneously 
form hydrogels in aqueous environments are of interest for drug and nucleic acid delivery 
and for cell and tissue engineering scaffolds.84,101,102 For example, LMW gelators based 
on glycosylated nucleoside amphiphiles were recently implemented as matrices/scaffolds 
for the culture of isolated stem cells.103 Moreover, the macroscopic reversibility or self-
healing characteristics LMW hydrogels allow additional mechanical manipulation and 
facile in vivo delivery methods (i.e., through a syringe104). 
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Due to their intricate associations, hydrogel networks present an opportunity to 
manipulate their architecture at the molecular level and nanoscale to trigger the release of 
entrapped agents. Drug delivery approaches involving stimuli-responsive hydrogels have 
been demonstrated using pH, temperature, ligand binding, and mechanical force as the 
triggering stimuli. We hypothesized that a low molecular weight hydrogel composed of 
self-assembled, reversible amphiphilic nanofiber entanglements could serve as an 
effective shear-responsive macromolecular drug depot. The goal of this work was 
therefore to investigate the mechanical properties of a low molecular weight hydrogel 
formed from gelator amphiphiles composed of biologically-relevant subunits, and apply 
the favorable self-healing, reversible properties of this gel to the delivery of 
macromolecules—specifically biopharmaceuticals. Herein we report the: 1) synthesis of 
low molecular weight hydrogels (LMWH) prepared from glycosyl-nucleoside-lipids 
(GNLs), which are amphiphiles composed of a polar sugar head, flexible nucleoside 
linker, and hydrophobic lipid tail; 2) viscoelastic mechanical properties of these 
hydrogels, including shear-thinning/injectability, and creep/recovery; 3) thermal and 
mechanical reversibility/self-healing properties; 4) macromolecular diffusion of FITC 
dextrans (as model biopolymers) within the gel matrix; 5) shear-mediated release of 167 
kDa FITC-dextran and an IgG directed against human TNFα, serving as a 
biopharmaceutical example; and 6) efficacy of this mechanoresponsive anti-TNFα 
delivery strategy in an in vitro cytokine neutralization assay. 
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2.2 Results & Discussion 
 
 
2.2.1 Synthesis & Characterization of Glycosyl-Nucleoside-Lipid (GNL) Hydrogels 
The oleoylamide GNL gelator (Figure 2.1A) was synthesized according to 
literature procedure89 with minor modifications, with an overall yield of ~65%, after a 
series of chemical reactions and purification via silica gel chromatography (Scheme 2.1). 
Upon heating and dissolution, the GNL gelator molecules self-assemble to form 
transparent hydrogels in aqueous media at 40 mg/mL (4 wt%, Figure 2.1B) through non-
covalent intermolecular forces, which include: hydrophobic interactions among the 
hydrocarbon chains; π-stacking of the nucleoside and triazole bridges; and hydrogen 
bonding among the thymidine, triazole, amide, and glucopyranoside moieties. Each 
component of this amphiphile structure is required to form a hydrogel.89 TEM 
experiments reveal the origin of the hydrogel as an intertwined network of ~12 nm 
diameter nanofibers (Figure 2.2A), and are in agreement with atomic force microscopy 
studies of GNL hydrogels deposited on mica, showing bundles of 11 nm-diameter fibers 
(Figure 2.2B). 
 
2.2.2 Viscoelastic Properties of GNL Hydrogels 
We measured the viscoelastic properties of GNL hydrogels as a function of 
temperature, frequency, and stress/strain amplitude using rotational shear rheometry, 
which is a sensitive, reproducible measurement technique for assessing the response of 
soft viscoelastic materials, such as hydrogels, to imposed mechanical stress under 
different testing parameters. In order to elucidate the direct effects each parameter has on 
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a material’s response, we first determined the linear viscoelastic region (LVR) using an 
oscillatory stress sweep at 1.0 Hz and 37 ºC. Within this regime, the elastic storage 
modulus (G’) and viscous loss modulus (G”) were ~20 Pa and 2 Pa, respectively (Figure 
2.3A). The yield stress occurred at 13.68 ±1.88 Pa, while the flow point (or critical yield 
stress) of the gel occurred at 27.29 ±3.75 Pa. Hydrogel stiffness (i.e., G’) was also 
dependent on concentration, with 8 wt% hydrogels exhibiting G’ and G’’ values of 55 Pa 
and 3 Pa, respectively (Figure 2.3B). Time sweeps of 4 wt% hydrogels indicated 
prolonged stability in response to shear (Figure 2.4). 
The frequency sweep study involved oscillations over the range of 0.1 to 100 Hz; 
however, due to the weak nature of the hydrogel, only meaningful data were obtained 
from 0.1 to 10 Hz before inertial effects (characterized by a raw phase angle ≥150 
degrees for this instrument) dominated the signal. Shear rate-dependent behavior was 
observed for this hydrogel, as complex viscosity (|η*|) decreases from 20 to 0.4 Pa·s with 
increasing shear rate/frequency (Figure 2.5A). These hydrogels also demonstrated the 
ability to be drawn up into a syringe and then ejected to re-form hydrogels, further 
confirming the shear-thinning, injectable nature of GNL hydrogels. Additionally, 
viscoelastic creep and recovery were observed on the time-scale of seconds using a 0.1 
Pa applied stress (Figure 2.6). 
 
2.2.3 Thermal & Mechanical Reversibility/Self-Healing Properties 
Temperature-dependent mechanics and thermal reversibility were investigated 
using a temperature sweep from 25 ºC to 58 ºC, and then down to 10 ºC at constant rates 
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of ±1.0 ºC/min, respectively. The data presented in Figure 2.7 indicated thermal 
reversibility for these hydrogels. A clear sol-gel transition was observed at ~56 ºC (red 
dashed line), although  begins to noticeably increase at temperatures ≥45 ºC. The 
macroscopic reversibility of these hydrogels was further determined by subjecting 
samples to three small- and large-amplitude oscillatory shear cycles (Figure 2.8) wherein 
the respective oscillatory stress alternated between 5.0 Pa (within the LVR), and 100 Pa 
(past the flow point for the gel). Values for  reversibly fluctuated from ~10 to >60 
degrees as the network ruptured and reformed.  The return to a hydrogel state occurred 
relatively fast, within <2 minutes, and there was no statistical change in mechanical 
response between the first and third cycle (p = 0.53 and p = 0.11 for 5 Pa and 100 Pa 
stresses, respectively). 
 
2.2.4 Macromolecular Diffusion Studies 
The diffusivity coefficients of fluorescein isothiocyante (FITC)-labeled dextrans 
within GNL hydrogels were determined by conducting fluorescence recovery after 
photobleaching (FRAP) experiments, illustrated in Figure 2.9A. Using confocal 
microscopy, fluorescence time-series micrographs of FITC-dextrans (19.6 kDa, 39 kDa, 
and 167 kDa), loaded at 0.5 mg/mL in 4 wt% GNL hydrogels, were acquired before and 
after photobleaching a 100-µm diameter region of interest. The average percent recovery 
curves after photobleaching for the three different MW dextrans are shown in Figure 
2.9B, and the diffusion coefficients (calculated using a MATLAB program based off the 
work of Jain et al.105), are listed in Table 2.1. The smallest molecular weight FITC-
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dextran (19.6 kDa) had the largest diffusivity coefficient—approximately 2.3 times 
greater than that of the largest FITC-dextran (167 kDa) tested. 
 
2.2.5 Shear-Mediated Release of FITC-Dextran 
Due to the soft and reversible nature of the hydrogel, it was hypothesized that 
shearing (i.e., rupturing the physical crosslinks) may influence the release rate of a large 
molecular weight (MW = 167 kDa) FITC-dextran (Scheme 2.2). A shear value of 10.0 Pa 
was selected based on the initial stress sweep data, which provided adequate stress to 
considerably disrupt the gel and nanofiber crosslinks (Figure 2.3A). A statistically 
significant increase in the release of 167 kDa FITC-dextran from GNL hydrogels was 
observed under 10.0 Pa shear compared to hydrogels at rest (Figure 2.10). 
 
2.2.6 Shear-Mediated Release of Anti-Tumor Necrosis Factor Alpha 
Shear-mediated macromolecule release was further studied using a rabbit 
immunoglobulin G (IgG) antibody directed against human tumor necrosis factor alpha 
(TNFα). Release aliquots of anti-TNFα from GNL hydrogels experiencing 10 Pa shear or 
no shear (control) were assessed for their ability to neutralize the cytotoxicity of human 
TNFα (IC50 = 51 pg/mL, Figure 2.11A) in the L929 murine fibroblast cell line. At a fixed 
concentration of 1 ng/mL TNFα, the corresponding Anti-TNFα antibody had a 
neutralization dose for 50% inhibition (ND50) of ~1 µg/mL (Figure 2.11B). The GNL 
hydrogels experiencing 10 Pa shear neutralized (i.e., reduced) TNFα toxicity by ~60% 
after 90 minutes, compared to ~10% neutralization for non-sheared antibody-loaded 
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hydrogels (Figure 2.12). The relative release of anti-TNFα for sheared and non-sheared 
samples was ~20% and ~5-10%, respectively, which was determined by comparing cell 
viability data to a previously-constructed TNFα neutralization curve performed with 
known concentrations of antibody. 
 
2.3 Conclusion 
 
A supramolecular chemistry approach was applied to the design of a functional, 
stimuli-responsive soft material constructed from bio-inspired amphiphiles. The hydrogel 
state, viscoelasticity, and observed mechanical properties arise from the entanglement of 
nanofibers assembled from individual GNL molecules. Dynamic stress sweeps on these 
hydrogels illustrate a linear viscoelastic region, followed by a deviation of the linear 
stress-strain relationship before gel rupture at the flow point. These gels are shear-
thinning/injectable, and data collected as a function of amplitude and temperature show 
predictable and reversible sol-gel transitions. 
The entangled nanofiber assemblies impede the diffusion of macromolecules 
within the gel matrix in a molecular weight-dependent fashion—as determined by FRAP 
studies—yet they may also be mechanically stressed to facilitate diffusion into the 
surrounding environment. A low molecular weight hydrogel that requires only mild 
gelation conditions and is capable of releasing biomacromolecules under applied shear 
stress may hold clinical promise as a mechanically-controlled delivery depot for 
therapeutic proteins such as enzymes and antibodies. Anti-TNFα was chosen as the 
model antibody in this study because of its broad clinical utility as an anti-inflammatory 
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agent (“TNF blocker”), such as in treating rheumatoid arthritis.106,107 Moreover, the 
availability of several cell lines with sensitivity to TNFα in the pg/mL range have 
allowed facile, reproducible, and sensitive measurements of both TNFα concentrations 
and the in vitro efficacy of anti-TNFα therapy using corresponding cytokine 
neutralization assays.108,109 
These studies highlight the utility of using supramolecular chemistry to design 
macroscopic functional materials, such as hydrogels, which may entrap delicate and 
bioactive substances for subsequent delivery,110 since the conditions for gel formation 
(and rupture) are mild, yet tunable. Mechanoresponsive biomaterials111,112 is an active 
area of biomedical research and has been demonstrated for the controlled delivery of 
growth factors63 and therapeutic agents73 from polymeric hydrogels and nanoparticles, 
respectively. Continued research in supramolecular chemistry offers further advances to 
stimuli-responsive materials, where the application of structure-function relationships 
found within biological moieties will afford new compositions of LMW gelators and 
materials tailored to specific biomedical applications. 
 
2.4 Materials & Methods 
 
2.4.1 Synthesis of GNL Gelators 
All reagents were purchased from Sigma-Aldrich unless otherwise noted and used 
as received. Dichloromethane (DCM), ethyl acetate (EtOAc), hexanes, acetonitrile 
(ACN), tetrahydrofuran (THF), dimethylformamide (DMF), and methanol (MeOH) were 
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purchased from Pharmco-Aaper, Brookfield, CT. Oleoylamide GNL was synthesized 
according to literature procedure89 (Scheme 2.1) with minor modifications. Briefly, 
equimolar oleoyl chloride and propargylamine were combined under N2 in anhydrous 
DCM containing 1.5-fold excess of triethylamine. The reaction was stirred overnight to 
yield N-propargyl oleoylamide (“activated lipid”), which was subsequently purified using 
silica gel chromatography (EtOAc/Hexanes 9:1; 90% yield). In a separate reaction, 5’-
Azido-5’-deoxythymidine (“activated nucleoside”) was synthesized starting from 
thymidine and 1.02 equivalents methanesulfonyl chloride and subsequent NaN3 (excess). 
Purification via hot crystallization in ACN resulted in white crystals in 60% yield. 
The first “click” reaction between lipid and nucleoside was carried out overnight 
in THF/H2O (50/50) at 65 °C with catalytic amounts of copper (II) sulfate and potassium 
ascorbate. The reaction was subsequently cooled, precipitated and dried en vacuo for 24 
hours. The compound was used in subsequent reactions without purification. 
Propargylation of the secondary amine on thymidine of the linked nucleoside-lipid was 
achieved using a two-fold excess of propargyl bromide and potassium carbonate in 
anhydrous DMF. The reaction was stirred at room temperature overnight, and heated en 
vacuo to remove DMF. After workup (DCM/H2O/brine washes), the compound was 
purified using silica gel chromatography (DCM/MeOH 9/1; 83% yield).  
Finally, this compound was mixed with an equimolar amount of 1-azido-β-(D)-
glucopyranoside; reaction conditions were identical to the “click” reaction described 
above. After column chromatography (EtOAc/MeOH 95/5 increasing to 85/15), the final 
compound was crystallized from a minimal amount of ethanol (88% yield).  
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The final GNL gelator structure and purity was confirmed by high-resolution 
mass spectrometry (HRMS) (ESI [M + Na]+, 852.4596 theoretical; 852.4597 actual), 
elemental analysis (57.88% C, 7.65% H theoretical; 57.65% C, 7.80% H actual), and 1H 
NMR. 1H NMR spectra were recorded at 93.94 kG (400 MHz) at ambient temperature. 
Proton chemical shifts were expressed in parts per million (ppm) relative to the residual 
proton solvent resonance: CDCl3 δ = 7.24. 
1H NMR (DMSO-d6): 0.85 (t, 3H), 1.24 (s, 20H), 1.45-1.49 (m, 2H), 1.88 (s, 3H), 
1.96-2.0 (m, 4H), 2.03-2.09 (m, 3H), 2.15-2.20 (m, 2H), 3.18-3.24 (m, 1H), 3.66-3.75 (m, 
2H), 4.08- 4.12 (m, 1H), 4.27 (d, 2H), 4.64-4.67 (m, 3H), 5.05 (s, 2H), 5.18 (d, 1H), 5.32-
5.36 (m, 4H), 5.48 (d, 1H), 5.57 (s, 1H), 6.23 (t, 1H), 7.50 (s, 1H), 7.90 (s, 1H), 8.11 (s, 
1H), 8.29 (t, 1H). 
 
2.4.2 Atomic Force Microscopy (AFM) Imaging of Hydrogels 
Hydrogels were dissolved in PBS with gentle heating and allowed to rest 
overnight. Twenty microliters of gel were deposited on freshly-cleaved mica discs (Ted 
Pella, Inc.) and rinsed twice with PBS. Measurements were performed in tapping mode at 
23 °C with an atomic force microscope (Asylum Research) using MLCT-C SiN tips 
having a spring constant of 20 pN/nm (Ted Pella, Inc.). 
 
2.4.3 Rotational Shear Rheometry 
Oleoylamide GNL (4 wt%) was dissolved in PBS via gentle heating. Samples 
were allowed to equilibrate 24 hours before testing. Rheometry was performed using a 
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stress-controlled TA Instruments AR1000 rheometer equipped with a 40-mm aluminum 
cone-plate geometry. For oscillatory stress sweeps, temperature and frequency were held 
constant at 37 °C and 1.0 Hz, respectively, while stress amplitude varied from 0.01-100 
Pa. The yield stress of the gels was defined as the stress value resulting in a noticeable 
change in the value of . The flow point (gel-sol transition) was interpreted as the point 
where G” (viscous component) overtook G’ (elastic component). Frequency sweeps 
between 0.1-100 Hz were conducted at 37 °C while keeping the applied stress at 5.0 Pa, 
within the linear viscoelastic region (LVR) for this material. Temperature sweeps at 1.0 
Hz and constant 4.0% strain were performed from 25-60 °C, and then down to 18 °C. 
Reversibility tests were performed by shearing at 37 °C within the LVR (5.0 Pa), resting 
for 2 minutes, and shearing at an amplitude beyond gel rupture (100 Pa). Each 
measurement of G’, G”, and  was performed in triplicate and on three different samples. 
 
2.4.4 Fluorescence Recovery after Photobleaching (FRAP) Studies 
FITC-labeled dextrans of 19.6, 39, 77, and 167 kDa molecular weights (Sigma-
Aldrich, Saint Louis, MO), and GNL hydrogels (4 wt %) were prepared from a 0.5 
mg/mL solution in distilled water for each of these species. The gels were subsequently 
imaged on an Olympus FV1000 scanning confocal microscope equipped with a 488 nm 
excitation laser and a second (405 nm) scan head, which supplied a 500-ms bleach pulse. 
Excitation laser power for imaging was set at 0.2%, and fluorescence emission was 
collected at 520 nm. Image acquisition rate was varied to obtain 200-300 time series 
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images (including three pre-bleach images) for each molecular weight. All imaging was 
carried out at 23°C on three different areas per sample. 
Data analysis for calculating the diffusion coefficient was performed by importing 
images into MATLAB, and calculating the average intensity within the region of interest 
(ROI) as a function of time. The curve of ROI average intensity versus time was 
Gaussian-fit with a step size of 0.001, according to the equations given by Jain et al. 
Solving these equations gave the diffusivity constant, D, in cm2/sec. Average pixel 
intensities within the ROI were normalized to percent recovery after photobleaching for 
graphical illustration (i.e., Figure 2.9B). 
 
2.4.5 Shear-Mediated Release of Biomacromolecules from GNL Hydrogels 
Hydrogels (4 wt%) were prepared using a solution of 0.5 mg/mL FITC-dextran 
(MW = 167,000 g/mol). Solid gelator was dissolved in this solution using mild heat and 
agitation, and the resulting gels were allowed to equilibrate overnight. The gel (0.7 mL) 
was added to the bottom of a glass petri dish (containing 60-grit aluminum oxide 
sandpaper) secured to the Peltier plate by double-sided tape. After lowering the geometry, 
25 mL of PBS was dispensed down the side of the dish wall using a syringe/needle. A 
time sweep was then performed on the sample for 90 minutes at 25 °C (10.0 Pa stress, 1 
Hz, 3 cycles per time point, 10 second delay time). The concentration of FITC-dextran 
released from the gel into the water bath was determined by withdrawing 1 mL aliquots 
at predetermined time points, measuring the emission maxima at 513 nm (excitation = 
490 nm), and then comparing these intensity values to a previously constructed standard 
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curve, using a quartz cuvette and fluorimeter with 0.5-mm slit widths. FITC-dextran 
release measurements from gels under the geometry, but experiencing zero shear over 90 
minutes, served as control samples. Frequent up-and-down pipetting of release medium, 
without disturbing the resting gels, was performed to facilitate uniform dispersion of 
FITC-dextran/anti-TNFα during the course of the experiments. Both control and 
experimental conditions were performed in triplicate. 
Hydrogels were similarly prepared with 180 µg of entrapped rabbit anti-huTNFα 
IgG (Abcam, Cambridge, MA) and loaded onto a glass dish as described above. A time 
sweep with parameters identical to those used for FITC-dextran release was performed 
for 90 minutes at 37 °C. At predetermined time points, 500-µL aliquots were withdrawn 
and assayed for efficacy in neutralizing the cytotoxic effect of human TNFα on L929 
murine fibroblasts (ATCC, Manassas, VA),108,109 which were cultured in RPMI 1640 
medium supplemented with 10% fetal bovine serum and maintained at 37 °C, 5% CO2 in 
a humidified incubator. The cytokine neutralization assay was performed at a final fixed 
concentration of 1 ng/mL human TNFα full-length protein (Abcam) by combining 50 µL 
release aliquots with 50 µL of TNF in reduced-serum (2%) medium. These mixtures were 
incubated for 2 hours at 37 °C before adding 50 µL to L929 cells in 96-well plates 
(seeded 18 hours prior at a density of 3 × 104 cells/well). An additional 50 µL of reduced-
serum media, containing 2 µg/mL actinomycin D (Sigma-Aldrich) were added to the cell 
plate. Viability percent (or % neutralization) of cells, relative to those incubated with 1 
ng/mL TNFα without anti-TNFα (negative control), or anti-TNFα only (positive control) 
were calculated using the colorimetric tetrazolium-based 3-(4,5-dimethylthiazol-2-yl)-5-
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(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega) by 
measuring absorbance at 492 nm using a 96-well microplate reader. Antibody 
concentration and percent release were finally calculated by comparing viability results to 
a separate TNFα neutralization dose-response experiment of known antibody 
concentrations. Both control and experimental conditions were performed in triplicate. 
 
2.4.6 Statistics 
Experimental values such as  and percent release of macromolecules were 
assessed for statistical significance using an unpaired, two-tailed t-Test, with statistical 
significance defined by values of p < 0.05. 
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Table 2.1 Diffusivity constants (D) for FITC-dextrans of different molecular 
weights, as determined using fluorescence recovery after photobleaching (FRAP). 
 
 
 
 
  
Molecular Weight 
(g/mol) 
Diffusion Coefficient, D 
(cm2/s) 
 
19,600 
 
1.13 × 10-7 
 
39,000 
 
0.93 × 10-7 
 
167,000 
 
0.50 × 10-7 
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Scheme 2.1 Synthetic route to oleoylamide glycosyl-nucleoside-lipid (GNL).  
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Scheme 2.2 Schematic diagram of shear-mediated release using a rheometer. 
Entrapped macromolecules, shown as antibodies in the figure, are slow to diffuse out into 
a water bath (light blue) due to the presence of GNL nanofiber entanglements (blue 
lines). Disrupting the nanofiber entanglements using applied shear stress facilitates their 
diffusion out of the network.  
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Figure 2.1 (A) Chemical structure of the oleoylamide glycosyl-nucleoside-lipid 
(GNL) highlighting the non-covalent interactions of each part of the amphiphile 
structure: hydrophobic (red), hydrogen-bonding (blue), and -stacking (pink). (B) 
Photograph of GNL hydrogel at 23 °C (left) and sol at 60 °C (right), which is above the 
gel-sol transition.  
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Figure 2.2 Microscopy of GNL hydrogel nanofibers. (A) TEM image of fibers 
formed from dilute GNL in aqueous solution, using uranyl acetate as a negative stain. (B) 
AFM image of hydrogel (height profile) diluted and deposited on freshly-cleaved mica, 
showing a bundle of GNL fibers with ~11 nm diameter.  
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Figure 2.3 Determination of LVR for GNL hydrogels using oscillatory stress sweeps 
at 37 °C and 1 Hz, showing concentration-dependent mechanical strength. (A) 4 wt% 
GNL hydrogel in PBS. (B) 8 wt% GNL hydrogel in PBS.  
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Figure 2.4 Time sweep of 4 wt% GNL hydrogel in PBS at 37 °C. 
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Figure 2.5 Frequency oscillation sweep of 4 wt% GNL hydrogel at 37 °C using 3.0 
Pa applied shear stress. Error bars for  represent ±SD for triplicate samples.  
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Figure 2.6 Creep curve for a 4 wt% GNL hydrogel at 37 °C under 0.1 Pa applied 
stress, and subsequent recovery after removal of shear stress. The vertical line at ~60 
seconds is an artifact of creep ringing in the sample, caused by step-stress inertial effects. 
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Figure 2.7 Thermal reversibility of GNL hydrogels. Oscillation temperature sweep of 
GNL hydrogel under 4.0% strain at 1 Hz. Error bars for  represent ±SD for triplicate 
samples. The red dashed line at ~56 °C represents the gel melting temperature. 
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Figure 2.8 Cyclic reversibility tests on hydrogels wherein the samples experience 
alternating small (5 Pa) and large (100 Pa) amplitude oscillatory shear stress, recovering 
their original mechanical properties after each cycle. Error bars represent ±SD for 
triplicate samples.  
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Figure 2.9 Macromolecular diffusion within GNL hydrogels shows molecular weight 
dependence. (A) Concept of fluorescence recovery after photobleaching. A region of 
interest (ROI) is selectively photobleached using focused high-intensity light (left), 
leading to a loss of fluorescence in the ROI (middle). Fluorescence recovery is a result of 
diffusion, where bleached fluorophores are displaced by unbleached fluorophores via 
Brownian motion. (B) Percent recovery after photobleaching for FITC-dextrans (19.6 
kDa, red; 39 kDa, blue; 167 kDa, black).  
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Figure 2.10 Percent release of 167 kDa FITC-dextran for sheared and non-sheared 
(control) samples, showing a statistically significant increase in macromolecular release 
after 90 minutes using 10 Pa applied shear stress (*p < 0.05). 
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Figure 2.11 In vitro L929 bioassay of TNFα-mediated toxicity and neutralization using 
rabbit anti-TNFα IgG. (A) TNFα dose-response curve using L929 murine fibroblasts 
sensitized with actinomycin D (1 µg/mL). (B) TNFα neutralization curve using L929 
cells at fixed concentrations of TNFα and actinomycin D (1 ng/mL and 1 µg/mL, 
respectively).  
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Figure 2.12 Shear-dependent delivery of rabbit anti-TNFα IgG from GNL hydrogels 
into the surrounding environment using 10 Pa applied oscillatory shear stress. The 
increased release of anti-TNFα under shear neutralizes TNFα cytotoxic activity to a 
greater extent than non-sheared control samples, as demonstrated in an in vitro L929 
bioassay (*p < 0.05). 
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CHAPTER 3:  Prevention of Lung Cancer Recurrence Using Cisplatin-Loaded 
Superhydrophobic Nanofiber Meshes 
 
 
3.1 Introduction 
 
Lung cancer is the leading cause of cancer deaths in North America, with over 
200,000 new cases diagnosed each year and a dismal 5-year survival rate of ~18%.113,114 
These survival rates improve to 54% if no metastatic disease is evident at the time of 
diagnosis. Surgery to remove the primary tumor is the standard of care in these ~50,000 
cases/year. Compared to surgical outcomes for early-stage breast and prostate cancer 
where 5-year survival rates are 90 and 99%, respectively, early-stage lung cancer survival 
is surprisingly poor.113 One of the factors contributing to poor survival is the inability of 
many patients to tolerate a “wide” local excision of their tumor (i.e., lobectomy), since 
removal of an estimated 25% of total lung function further compromises already limited 
pulmonary function. Lesser (i.e., wedge) resections save lung parenchyma but are 
associated with a two-fold increase in local cancer recurrence as a result of the 
microscopic disease remaining at the surgical resection margin.115,116 This is a critical 
decision since current 2-year survival in patients that develop local recurrence drops to 
~20% as the majority of these patients are not candidates for additional surgery, and 
radiation and/or chemotherapy are largely palliative.117 Platinum-based DNA-adducting 
agents, such as cisplatin, are the current standard-of-care chemotherapy for lung 
cancer.118,119 Although these agents have dose-limiting side-effects such as 
nephrotoxicity120 and neurotoxicity121 with systemic administration, the use of cisplatin 
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has achieved some improvement in overall survival for lung cancer patients with 
metastatic disease. Cisplatin has also been used in combination therapy118,119,122,123 to 
achieve a wider therapeutic window and hence better clinical outcomes. Given the 
limitations in cisplatin dosing, several clinical trials have been or are currently being 
conducted to improve lung cancer outcomes using cisplatin in conjunction with other 
agents such as 5-fluorouracil,124 gemcitabine,125 and targeted therapies involving small-
molecule inhibitors or monoclonal antibodies.126-129 
Other approaches to improve cisplatin efficacy in vivo are also being investigated. 
Nanoparticles, targeted therapy, and local drug delivery strategies such as chemotherapy-
loaded films, foams, and gels are all being developed to improve drug uptake while 
minimizing systemic side effects.130 In particular, cisplatin-loaded nanoparticles have 
been evaluated in several clinical trials with promising results,131,132 and other cisplatin 
drug delivery materials such as gels,133 films,134 and glues135 designed for local 
administration are gaining traction in the fight against lung and related thoracic cancers. 
However, many local and systemic drug delivery systems possess burst release kinetics, 
which exposes drugs to tumors for only a short duration and highlights the need for 
improving the arsenal of sustained-release chemotherapy depots. 
We have recently reported the fabrication of 3-dimensional superhydrophobic 
microfiber meshes that utilize the metastable air barrier within these porous materials to 
drastically slow wetting and thereby sustain the release of encapsulated 7-ethyl-10-
hydroxycamptothecin,136 an experimental lipophilic anticancer agent, for several weeks. 
Given the central role of cisplatin therapy in the treatment of lung cancer, this report 
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focuses on efforts using superhydrophobic materials to deliver this hydrophilic drug. 
Specifically, the current report describes the fabrication of cisplatin-loaded, three 
dimensional nanofiber meshes; demonstrates the sustained release of cisplatin in vitro; 
and applies the favorable physical and mechanical properties of these biodegradable 
meshes to an in vivo surgical model of aggressive, early-stage lung cancer and local post-
surgical cancer recurrence. 
 
3.2 Results 
 
3.2.1 Electrospinning & Mesh Characterization 
Nanofiber meshes containing 3% (w/w) cisplatin were successfully prepared from 
a 20% (w/v) solution blend of 70% polycaprolactone (PCL) and 30% of the low surface 
energy copolymer poly(glycerol monostearate-co-caprolactone) (PGC-C18) (Figure 3.1A 
and Figure 3.1B, respectively) using the electrospinning process. The operational 
parameters for electrospinning are presented in Table 3.1. Pure PCL meshes were also 
fabricated under similar parameters. The resulting fiber jet was deposited onto a 
grounded, rotating (50 rpm) and linear-translating aluminum cylinder, permitting 
production of meshes up to ~100 cm2 (Figure 3.1C). SEM imaging of electrospun 
meshes depicted their underlying architecture of ~500 nm diameter entangled fibers 
(Figure 3.2), which were significantly thinner than those electrospun from a more 
commonly used solution of 5:1 chloroform:methanol (6 µm).137 Contact angle (CA) 
goniometry studies revealed pure PCL meshes were moderately hydrophobic (CA = 
133°), whereas the addition of 30% (w/w) PGC-C18 rendered meshes superhydrophobic 
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(CA >150°). The PGC-C18 copolymer has a lower surface energy than that of PCL, (CA = 
120° and 88° on smooth films, respectively, Figure 3.3), and contributed to the 
superhydrophobic state. 
 
3.2.2 Biocompatibility Studies 
Given that PCL is a biocompatible and widely-used polymer, a series of in vitro 
and in vivo safety studies based on ISO-10993 and FDA G95-1 guidelines for PGC-C18 
were performed under GLP conditions at Toxikon with appropriate protocols and 
assurances in place. The results of these tests are as follows: 
 Cytotoxicity: Agar Diffusion (ISO 10993-5). No biological reactivity was 
observed in L929 mammalian cells at 48 hours post-exposure. The polymer was 
considered non-cytotoxic. Pass. 
 Genotoxicity: Ames Assay/Salmonella & E coli (ISO 10993-3). No statistical 
increase in revertant colonies was observed with the PGC-C18 as compared to the 
negative control. PCG-C18 was not considered mutagenic. Pass. 
 Intracutaneous Injection (ISO 10993-10). Injection of the NaCl extract of the 
polymer in rabbits did not show a significantly greater biological reaction (i.e., 
irritation) than sites injected with the control. Pass. 
 Hemolysis (ISO 10993-4). The polymer exhibited 0.00% hemolysis above the 
level of the hemolysis exhibited by the positive control. The polymer was 
considered non-hemolytic using ASTM method F756-08. Pass. 
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 Kligman Maximization (ISO 10993-10). The polymer extracts did not elicit any 
significant allergic or sensitizing response in guinea pigs over the 25-day test 
period. Pass. 
 Systemic Injection (ISO 10993-11). Injection of the polymer extract did not induce 
a significantly greater biological reaction in mice than the control extract. Pass. 
 Abridged 28 Day Sub-Acute Systemic Toxicity by Implant (ISO 10993-11). This 
test assessed adverse effects after administration of PGC-C18 films for 28 days. 
This study included 40 rats (20 male, 20 female), subcutaneous implantation of 
test or control article, daily health observations, weekly body weights and detailed 
observations, blood collected at termination for hematology and clinical 
chemistry, gross necropsy with histopathology of implant sites and up to 9 tissues, 
and body and organ weights. For all parameters, the implant did not demonstrate 
any local or systemic signs of toxicity. The bioreactivity rating for the 28 day time 
period was 0.0, indicating no reaction. Pass. 
 
3.2.3 In Vitro Release Kinetics & Efficacy Against a Lung Cancer Cell Line 
The drug release behavior of cisplatin-loaded nanofiber meshes submerged in 
PBS (supplemented with 10% fetal bovine serum) and mechanically shaken at 37 °C is 
presented in Figure 3.4. While pure PCL meshes rapidly released >95% of their cisplatin 
payload within 24 hours, less than 1% was released from superhydrophobic PCL/PGC-
C18 meshes. The release of cisplatin was linear over ~90 days under these conditions, 
which corresponded to a dose of ~3 µg cisplatin/day (film mass = 10 mg). Using a 
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transwell assay,136 cisplatin-loaded superhydrophobic meshes were efficacious in vitro 
against the Lewis Lung Carcinoma (LLC) cell line for over 70 days, while non-
superhydrophobic PCL meshes were cytotoxic for the first day of exposure only (Figure 
3.5). Bulk wetting of unloaded meshes was also quantified using contrast-enhanced 
microcomputed tomography (µCT) and an iodinated contrast agent dissolved in the 
surrounding medium (Figure 3.6). This confirmed that the PCL meshes wetted rapidly in 
~1 day, while superhydrophobic meshes resisted wetting for >60 days. The wetted 
volume fraction also increased in an approximately linear fashion (R2 = 0.9) as a function 
of submersion duration (Figure 3.7). 
 
3.2.4 Mechanical Properties & Surgical Stapling Capabilities of Meshes 
The mechanical behavior of meshes was investigated by subjecting specimens to 
uniaxial tensile testing. Representative stress-strain curves for cisplatin-loaded PCL and 
PCL/PGC-C18 meshes and their unloaded counterparts are shown in Figure 3.8. There 
were no discernable differences in the stress-strain curves among drug-loaded and 
corresponding unloaded meshes. Compared to PCL meshes, incorporation of 30% PGC-
C18 within the PCL meshes afforded a slightly weaker material in terms of ultimate 
tensile strength (1200 kPa versus 800 kPa, respectively). Meshes were also cut into strips, 
loaded into a standard surgical stapler (Figure 3.9A), and then stapled (Figure 3.9B). As 
shown by SEM, the mesh conforms around the staple (Figure 3.9C). 
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3.2.5 Efficacy in an In Vivo Lung Cancer Recurrence Model 
Cisplatin-loaded meshes were evaluated for their efficacy in preventing local 
cancer recurrence in C57BL/6 mice using a surgical model of cancer that assesses 
freedom from local recurrence following surgical excision (Figure 3.10).138 This model 
involved establishing LLC tumors (>300 mm3) subcutaneously on the backs of mice, 
followed by surgical resection and treatment. Treatment groups included: 1) a cisplatin-
loaded superhydrophobic mesh (13.2 mg/kg equivalent dose) implanted at the resection 
site; 2) implantation of an unloaded superhydrophobic mesh; 3) implantation of an 
unloaded superhydrophobic mesh and intraperitoneal (i.p.) cisplatin (2 doses × 6.6 
mg/kg); or 4) only i.p. cisplatin 2 × 6.6 mg/kg. Without chemotherapy, resected control 
animals developed local recurrences within a median of 6 days (Figure 3.11). Cisplatin, 
administered in two 6.6 mg/kg doses, separated by one week due to single-dose toxicity 
limitations,139 had a marginal effect in preventing local recurrence (8 versus 6 days for no 
additional treatment, p > 0.05). In contrast, the median freedom from local recurrence 
was significantly increased for mice treated with cisplatin-loaded meshes compared to 
those treated with i.p. cisplatin (p = 0.0006). All animals tolerated systemic and drug-
loaded mesh treatments, with no statistically significant differences in changes in mean 
body weight across all groups (linear regression analysis, p > 0.05). On day 8 after 
surgery, only the body weights of mice treated with i.p. cisplatin were lower than those of 
mice treated with unloaded mesh and i.p. saline (18.1 ± 0.27 g versus 20.1 ± 0.30 g, 
respectively, ANOVA, p < 0.05). Histologic evaluation of all mesh specimens revealed a 
mild chronic inflammatory infiltrate and granulation tissue immediately adjacent to the 
 
 
 
80 
material. The overlying normal skin and adjacent skeletal muscle showed no evidence of 
necrosis or other pathologic change as a result of implantation of the mesh. There was no 
histologic difference in tissue reaction between unloaded and cisplatin-loaded meshes 
(Figure 3.12A and Figure 3.12B, respectively). 
 
3.3 Discussion 
 
Given the need to minimize the amount of lung removed and yet achieve 
histologically negative margins, a local drug delivery approach that supplements 
cytoreductive surgery with localized, sustained-release chemotherapy may hold promise 
by eliminating residual, microscopic tumor cells—particularly in patients unable to 
tolerate more aggressive resection. Such a local drug-delivery approach is currently 
clinically implemented in the treatment of only one cancer: high-grade malignant glioma. 
After cytoreductive surgery, rigid, brittle carmustine (BCNU)-loaded polyanhydride 
wafers are placed in the resected tumor beds, with BCNU release occurring over 2-3 
weeks.140 For patients with newly diagnosed malignant glioma, this treatment increased 
their median survival to 64.1 weeks, compared to 49.4 weeks with placebo.140,141 Further 
success has been limited by the short duration of drug release in this delivery system. 
Unlike static tissues, the functional difference of reversible tissue extension and 
contraction present on the lung surface necessitates the use of compliant materials for 
drug delivery. Therefore, the design characteristics for drug delivery to the lung required 
a compliant, flexible material with a prolonged release profile. 
 
 
 
81 
Accordingly, we previously developed paclitaxel-loaded PGC-C18 films for 
preventing local cancer recurrence in a similar LLC tumor resection model.138 These 
films relied on their hydrophobicity to provide sustained drug release over ~90 days for 
lipophilic drugs (such as paclitaxel138 and 10-hydroxycamptothecin142). However, these 
films lacked the mechanical integrity to serve as buttressing materials themselves and 
were therefore cast atop secondary scaffolds composed of de-cellularized bovine 
pericardium strips. Ideally, this system should be a single component with dual-
functionality—providing both buttressing and sustained drug release without reliance on 
animal-derived components—so as to facilitate and simplify manufacturing, quality 
control, and regulatory matters. 
In order to fabricate an all-in-one drug-device system that could also be stapled 
into the lung tissue using standard surgical staplers, the technique of electrospinning was 
selected. Electrospinning is a polymer processing technique143 that generates non-woven 
fiber meshes and involves the application of high voltage to a polymer solution at the tip 
of a syringe pump and needle assembly. The balancing of electrostatic repulsion and 
droplet surface tension results in a jet emanating from the end of the droplet, with 
subsequent solvent evaporation as this jet whips through the air toward a grounded 
collector. The common chloroform/methanol solvent system for electrospinning PCL-
based meshes was avoided because cisplatin is insoluble in such nonpolar solvents, and 
solvent-drug compatibility has been shown to affect drug release rates and/or result in 
poor encapsulation.144 Therefore, a solvent mixture of dichloromethane/dimethyl-
formamide was used to ensure solubility of both polymers and cisplatin. Cisplatin-loaded 
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meshes were 600 µm thick and composed of fibers approximately 500 nm in diameter. 
The electrospinning collector apparatus yielded large meshes (100 cm2) that could 
subsequently be cut to specific shapes and sizes to facilitate coverage of the entire tumor 
bed and to allow surgical buttressing and stapling along the tumor margins. Fabricating 
meshes by electrospinning improves the mechanical flexibility of the PCL and PGC-C18 
polymer blend resulting in strong, yet compliant meshes. Meshes can be rolled or twisted 
without tearing, and their ultimate tensile strengths are greater than those reported for 
lung tissue145,146 and similar to buttressing materials currently used in the operating room 
to ensure an air-tight seal after stapling to the resected tissue.147 
One of the consequences of using a mesh rather than a film construct is the 
significant increase in the surface area/volume ratio present with meshes, resulting in 
faster drug release as compared to films. Furthermore, sustained-release of cisplatin is 
particularly challenging due to its relatively high solubility in aqueous solution (1 
mg/mL, log P = -2.35;148 compared to < 0.01 mg/mL, log P =3.96 for paclitaxel,149 for 
example). An additional challenge is due to the poor solubility of cisplatin in nonpolar 
solvents, resulting in burst release kinetics and limiting the methods available to fabricate 
such drug delivery devices. Previously, the longest reported duration of release for 
cisplatin-eluting electrospun meshes was ~35 days;150 and even then release behavior was 
still largely dominated by burst kinetics. In contrast, this approach relies on slowing the 
wetting rate of the meshes, and thus the rate of drug release, through the use of a 
metastable superhydrophobic state present within the meshes. Preventing burst release of 
water-soluble agents using superhydrophobic materials are being actively explored by 
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other researchers, where these agents have been incorporated into superhydrophobic 
polymer electrolyte multilayered films.151 
In the current formulation, cisplatin release is devoid of burst release, and the 
profile is gradual and linear for ~90 days with 3 µg cisplatin released per day from the 
superhydrophobic PCL/PGC-C18 meshes. In contrast, the hydrophobic meshes composed 
of PCL release their entire payload within the first several days. Likewise, artificially 
wetting the superhydrophobic meshes with a 70% ethanol/water mixture causes the rapid 
release of cisplatin, and the kinetics mirror those of the PCL meshes (Figure 3.13). 
Importantly, cisplatin-loaded superhydrophobic meshes exhibit cytotoxicity against LLC 
cells for a similar 70-day period as the release profile, whereas cisplatin-loaded PCL 
meshes are not cytotoxic by day 5. Moreover, drug release (and associated in vitro 
cytotoxicity) from the superhydrophobic PCL/PGC-C18 meshes mirrors the rate and 
linearity of their wetting, as measured by contrast-enhanced µCT, and indicates drug 
release is due to mesh hydration. These results suggest the potential to apply this general 
strategy to several other potent water-soluble drugs used in the treatment of lung and 
other cancers, such as doxorubicin hydrochloride, gemcitabine, and pemetrexed, and will 
be the subject of future studies. 
The promising anti-cancer efficacy of these meshes against LLC cells prompted 
evaluation of their efficacy in preventing local lung cancer recurrence in an in vivo tumor 
resection model. The LLC cell line is murine-derived, aggressively tumorigenic, and 
responds poorly to chemotherapy. This local cancer recurrence surgical model involves 
inoculating LLC tumors subcutaneously in the backs of wild-type mice, and then 
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performing tumor resection followed by one of several subsequent treatments (cisplatin-
loaded mesh, unloaded mesh and i.p. saline, i.p cisplatin, and unloaded mesh with i.p 
cisplatin). Cisplatin-loaded superhydrophobic meshes prevented local tumor recurrence 
in 5/9 mice (56%), proving superior to all other groups (p < 0.0001). Histological 
evaluation of excised meshes showed a mild chronic inflammatory response, which is 
typical and acceptable for implanted biocompatible materials. These results are consistent 
with the findings from the ISO 10993 biocompatibility study performed on the PGC-C18 
copolymer, and with the known biocompatibility of PCL and PCL electrospun 
meshes.152,153 
Taken together, the current study builds upon our prior work investigating local 
drug delivery devices for the prevention of recurrence following resection of localized 
lung cancer. The advances identified in the current manuscript are: 1) an improved form 
factor to a single system that provides tissue buttressing and drug delivery; 2) the use of 
electrospinning as a scalable manufacturing method; 3) fabrication of a compliant mesh 
capable of surgical stapling; 4) the successful completion of FDA-required 
biocompatibility testing on the PCG-C18 copolymer component of these 
superhydrophobic meshes; 5) identification of a superhydrophobic mesh composition for 
controlled and sustained delivery of a hydrophilic drug (i.e., cisplatin) over several 
months; and 6) superior outcomes in an in vivo murine tumor resection model using 
cisplatin-loaded superhydrophobic meshes compared to equivalent systemic dosing. 
Lastly, GMP production of 1 kg of PGC-C18 was completed at a contract research 
organization, and this material will enable us to perform the next crucial pharmacokinetic 
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studies to determine the organ distribution of cisplatin after drug-loaded meshes are 
applied to resected lung tissue in an ovine model. 
 
3.4 Conclusion 
 
The increased risk of recurrence following wedge resection for lung cancer is due 
to the presence of occult microscopic disease remaining after surgery. Thus, to avoid 
recurrent disease and yet spare as much “normal” lung as possible, new local treatments 
at the site of tumor resection are being sought. We addressed this challenge by designing 
a local drug delivery buttressing device for the sustained release of cisplatin. To 
overcome the burst release kinetics commonly found with cisplatin delivery systems, we 
fabricated a biodegradable, biocompatible electrospun nanofiber mesh that exhibits bulk 
metastable superhydrophobicity, and thus is water repellent and porous. The progressive 
wetting of these meshes over time acts as a gradual, sustained release mechanism for 
cisplatin. The macroscopic mesh structure provides mechanical stability and flexibility 
while being amenable to stapling with a standard surgical stapler used in lung resection 
procedures. Lastly, the positive results of our in vivo murine model of lung cancer 
recurrence reinforce the concept of using principles of drug delivery, polymer chemistry, 
and biomaterials science to drive the innovation of multifunctional materials for cancer 
treatment. 
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3.5 Materials & Methods 
 
3.5.1 Chemicals & Reagents 
Polycaprolactone (MW 70-90 kg/mol), cisplatin (≥ 99.9%), dichloromethane 
(DCM, reagent grade ACS), anhydrous N,N-dimethylformamide (DMF, 99.8%), 
diatomaceous earth (Celite® 545), stearic acid (95%), N,N’-dicyclohexylcarbodiimide 
(DCC,  99.9%), toluene (anhydrous, 99.8%), tin(II) ethylhexanoate (~95%), ε-
caprolactone (97%), nitric acid (60-70%), and TritonTM-X 100 were purchased from 
Sigma-Aldrich and used as received. Methanol and tetrahydrofuran (THF) were of 
reagent grade and purchased from Pharmaco-Aaper. Palladium on carbon (Pd/C, 10% on 
activated wood carbon, unreduced, ~50% water wet paste) was purchased from Strem 
Chemicals. DMEM and penicillin/streptomycin were purchased from Gibco, and fetal 
bovine serum was purchased from Atlanta Biologicals. 
 
3.5.2 Synthesis of Poly(caprolactone-co-glycerol monostearate) 
Poly(caprolactone-co-glycerol-monostearate) (PGC-C18) was synthesized 
according to literature procedure,154 as illustrated in Scheme 3.1. Briefly, the monomer 5-
benzyloxy-1,3-dioxan-2-one and ε-caprolactone were reacted at 140 °C for 20 hours in a 
ring-opening polymerization catalyzed by tin(II) ethylhexanoate (0.005 eq.). The polymer 
was cooled, dissolved in DCM, and precipitated into cold methanol (90% yield). After 
filtration, the polymer was dissolved in THF and hydrogenated at 50 psi for 4 hours at 
room temperature using Pd/C. The catalyst was filtered out through a bed of 
diatomaceous earth and precipitated into cold methanol (93% yield). Next, stearic acid 
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(1.5 eq.) was grafted onto the free secondary hydroxyl group using standard N,N’-
dicyclohexylcarbodiimide (DCC) coupling for 18 hours. The mixture was filtered and 
concentrated three times before precipitating twice into cold methanol, and dried under 
high-vacuum for 24 hours (88% yield). Molecular weight was determined using size 
exclusion chromatography with a Polymer Laboratories PLgel MIXED-E column (3-µm 
bead size) and a Rainin HPLC solvent delivery system using THF as the eluent (1.0 
mL/min, 25 °C). PGC-C18 molecular weight (Mn) was calculated at ~40,000 g/mol 
(Mw/Mn = 1.5) using polystyrene calibration standards (Polysciences, Inc.). 
1H NMR of 
the polymer agreed with previous reports.142,154 
 
3.5.3 Biocompatibility Studies of PGC-C18 
Biocompatibility testing of PGC-C18 involved a series of in vitro and in vivo 
studies conducted according to ISO-10993 and FDA G95-1 guidelines. These tests were 
performed under GLP conditions at Toxikon, Inc. with appropriate protocols and 
assurances in place. 
 
3.5.4 Electrospinning Cisplatin-Loaded Nanofiber Meshes 
Dichloromethane (1.5 mL) was added to a 20-mL glass scintillation vial 
containing PCL pellets (910 mg) and PGC-C18 (390 mg) and allowed to dissolve 
overnight. DMF (2.5 mL) was then added to this solution and thoroughly vortexed over 
12 hours. A solution of cisplatin (40 mg in 2.5 mL DMF) was then added to the polymer 
solution and vigorously mixed. The solution was loaded into a 10-mL glass syringe 
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equipped with an 18 AWG needle. Solutions of PCL only (1.3 g) with 3% (wt/wt) 
cisplatin, and polymer solutions without drug, were also prepared. 
 
3.5.5 Characterization of Meshes 
Scanning electron microscopy (Zeiss Supra V55) was performed to assess the 
morphology of electrospun meshes and determine fiber diameter. Meshes were cut to 0.3 
x 0.3 cm2, mounted on aluminum stubs using conductive copper tape, and imaged at 2 
keV. Advancing and receding water contact angle measurements using a goniometer 
(Kruss DSA100) were performed to characterize the non-wetting nature of meshes. 
Tensile properties of meshes (1.5 cm x 4 cm) were determined using an Instron 5848 
tensile testing apparatus at a 1 mm/s elongation rate and a 10N load cell. Surgical stapling 
was performed using an Endo GIATM Ultra 12-mm single-use short universal stapler 
(Covidien, Ltd.). A poly(glycolic acid) surgical mesh (NEOVEIL, Gunze Limited) was 
stapled for comparison. 
 
3.5.6 Drug Release Studies 
Sink conditions for release experiments consisted of phosphate-buffered saline 
(PBS) supplemented with 10 % (v/v) fetal bovine serum (FBS), 100 U/mL penicillin, and 
100 µg/mL streptomycin. A volume of 15 mL was used for meshes (~10 mg), which was 
replaced weekly, ensuring >10-fold solubility excess for maintaining sink conditions. 
Meshes and release medium were sealed in 15-mL polypropylene centrifuge tubes and 
incubated on a shaker in a 37 °C incubator. Aliquots (3 × 100 µL) were withdrawn at 
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predetermined time points and frozen at -20 °C until further use. Cisplatin concentration 
was determined using flameless atomic absorption spectrophotometry (Varian AA240Z) 
using pyrolytic graphite-coated, partitioned tubes and Zeeman background subtraction,155 
using a hot pre-injection of TritonTM-X 100 (5 µL) at 50 °C. 
 
3.5.7 Micro-Computed Tomography (µCT) Study of Mesh Hydration 
 Microcomputed tomography studies were performed by incubating meshes in 
PBS supplemented with 10% FBS and 80 mgI/mL iodixanol (GE Healthcare). Meshes 
were periodically removed from culture and assessed for water infiltration (i.e., contrast 
agent solution) using a Scanco Medical µCT40 imaging system as previously 
described,156 with an isotropic voxel resolution of 36 µm3, 70 kVP tube voltage, 114 µA 
current, and 300 ms integration time. Image slices were converted into the standard 
image format (DICOM) using proprietary software from Scanco Medical. Data were 
reconstructed and analyzed using a commercial image processing software (AnalyzeTM, 
Mayo Clinic). 
 
3.5.8 Cell Culture 
The Lewis Lung Carcinoma (LLC) murine cell line was used to demonstrate in 
vitro efficacy of cisplatin-loaded superhydrophobic meshes. Cells were plated in 12-well 
plates at a seeding density of 3×104 cells/well in DMEM supplemented with 10% FBS, 
100 U/mL penicillin, 100 µg/mL streptomycin and grown overnight at 37 °C in a 
humidified 5% CO2 incubator. The following day, meshes were added to transwell inserts 
 
 
 
90 
(200-µm pore size) and rinsed three times with PBS and aspirated to remove the liquid. 
Cell culture media was then aspirated from the LLC-containing plates, followed by 
addition of the transwell inserts (Corning). Fresh complete cell culture medium was then 
added to the bottom of the well (1.0 mL) and on top of the mesh (0.5 mL) to ensure 
meshes were submerged in media. After 24 hours’ co-incubation with meshes, meshes 
were removed from each well, and cells were incubated an additional 48 hours before 
aspirating media and assessing for viability using the colorimetric MTS assay. Fresh LLC 
cells were plated every 5 or 10 days to assess the sustained release efficacy of cisplatin 
loaded meshes, and these meshes were maintained in complete cell culture medium (1.5 
mL) when not co-incubated with cells. 
 
3.5.9 In Vivo Murine Model of Local Cancer Recurrence 
Animal studies were approved by the Institutional Animal Care and Use 
Committee at Brigham and Women’s Hospital. A total of 36 C57BL/6 female mice were 
injected subcutaneously (s.c) with 7.5 × 105 LLC cells and allowed 2-3 weeks for tumors 
to reach more than 300 mm3. Tumors were then resected, and mice were subsequently 
randomized and split into four groups for subsequent treatment: 1) cisplatin-loaded 
superhydrophobic meshes (1.2 x 1.2 cm2) at an equivalent dose of 13.2 mg/kg implanted 
at the time of surgery; 2) two doses of intraperitoneal (i.p) cisplatin in saline (6.2 mg/kg) 
administered one week apart; 3) unloaded superhydrophobic meshes implanted at the 
time of surgery, followed by two i.p cisplatin doses (6.2 mg/kg) administered one week 
apart; 4) unloaded superhydrophobic meshes implanted at the time of surgery, followed 
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by two i.p saline injections administered one week apart. Mice were monitored for 
freedom from local recurrence, with local recurrence defined as tumor(s) present 
anywhere on the back of animals. Data are presented as the mean ± SEM. A log-rank 
(Mantel-Cox) test was used to assess efficacy of the various treatment groups for 
statistical significance in prolonging tumor-free recurrence, and linear regression was 
used to compare changes of body weights over time between animals in different 
treatment groups. Prism 5.0 (GraphPad, La Jolla, CA) was used for all statistical 
analyses. Histological assessment of the tissue response to implanted unloaded and 
cisplatin-loaded meshes were performed by excision and fixation in 10% formalin, 
followed by paraffin embedding. Sections (4 µm thick) were stained with hematoxylin 
and eosin. Images were obtained at 200X magnification using an Olympus BX41 
microscope coupled to an Olympus BP70 digital camera (Olympus America Inc., Center 
Valley, PA.) Adobe Photoshop software (Adobe Systems, San Jose, CA) was used to 
adjust the white balance of the images. 
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Table 3.1 Electrospinning parameters for fabricating PCL and PCL/PGC-C18 
meshes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Mesh Composition Voltage (kV) Flow Rate (mL/h) Distance (cm) 
PCL + cisplatin 16 3 15 
PCL/PGC-C18 + cisplatin 19 3 13 
PCL (unloaded) 15 2.5 13 
PCL/PGC-C18 (unloaded) 15 2.5 13 
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Scheme 3.1 Polymerization of poly(ε-caprolactone-co-glycerol monostearate). In this 
reaction, the monomers ε-caprolactone and 5-benzyloxy-1,3-dioxan-2-one are reacted in 
a 4:1 molar ratio, respectively, and polymerized with the catalyst tin(II) ethylhexanoate 
(Sn(oct)2) at 140 °C under nitrogen. Polymer 1 is then reacted with palladium/carbon 
(Pd/C) with 50 psi hydrogen to yield polymer 2. Stearic acid (C18:0) was subsequently 
grafted onto the free hydroxyl (—OH) using DCC coupling chemistry to obtain poly(ε-
caprolactone-co-glycerol monostearate) (polymer 3).  
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Figure 3.1 Fabrication of electrospun superhydrophobic PCL-based nanofiber 
meshes. (A) Molecular structure of PCL, the main polymer component of these 
electrospun meshes. (B) Molecular structure of the superhydrophobic dopant copolymer 
poly(ε-caprolactone-co-glycerol monostearate) (PGC-C18). (C) A cisplatin-loaded 
electrospun superhydrophobic mesh of ~100 cm2 area.  
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Figure 3.2 SEM images and static water contact angle measurements on cisplatin-
loaded nanofiber meshes. (A) Superhydrophobic PCL/PGC-C18 mesh with ~500 nm 
diameter fibers. A water droplet on its surface exhibits a contact angle of 151°. (B) Non-
superhydrophobic mesh (composed of PCL only) with ~500 nm diameter fibers. A water 
droplet on its surface exhibits a contact angle of 135°.  
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Figure 3.3 Contact angle measurements on smooth casted films of polycaprolactone 
(grey, left) and poly(glycerol monostearate-co-caprolactone) (red, right). 
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Figure 3.4 Cumulative release of cisplatin from electrospun PCL-based meshes. The 
left y-axis describes cisplatin release as a percentage of initial drug loading within 
meshes, whereas the right y-axis describes cisplatin release in terms of quantity (mass) of 
drug released. Dashed line represents linear-best fit of cisplatin release from PCL/PGC18 
meshes (0.8% or 3 µg/day) in 10% serum with shaking. Inset shows cisplatin release 
from pure PCL meshes in 10% serum (top curve) and PBS (bottom curve).  
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Figure 3.5 Assessment of prolonged in vitro efficacy of cisplatin-loaded electrospun 
meshes against Lewis Lung Carcinoma (LLC) cells. Non-superhydrophobic, cisplatin-
loaded PCL meshes are shown in grey; superhydrophobic, cisplatin loaded PCL/PGC-C18 
meshes are shown in black. Error bars represent ± SD (n = 3). 
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Figure 3.6 Contrast-enhanced microcomputed tomography (µCT) analysis of bulk 
wetting of (A) electrospun PCL meshes and (B) electrospun superhydrophobic 
PCL/PGC-C18 meshes. Hydration was assessed by incubating meshes in PBS 
supplemented with 10% (v/v) FBS and 80 mgI/mL iodixanol, a commercially available 
radiocontrast agent, at 37 °C. Regions appearing as blue/green represent wetted mesh 
(i.e., the presence of water and contrast agent), whereas red areas represent air and/or 
non-wetted mesh.  
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Figure 3.7 Quantification of bulk wetting of superhydrophobic PCL-based meshes 
using contrast enhanced microcomputed tomography (µCT). Error bars represent ± SD (n 
= 3). 
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Figure 3.8 Stress-strain curves for non-superhydrophobic electrospun PCL meshes 
(black) and superhydrophobic electrospun PCL/PGC-C18 meshes (grey). Cisplatin-loaded 
meshes are depicted by solid lines, while unloaded meshes are depicted by dashed lines.  
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Figure 3.9 Surgical stapling capabilities of electrospun superhydrophobic meshes. 
(A) A strip of mesh ~1 cm wide being loaded into a surgical stapler. (B) Stapled 
superhydrophobic mesh (top) compared to a clinically-used fibrous surgical buttress 
(bottom). (C) SEM image of surgically-stapled superhydrophobic mesh (scale bar = 200 
µm).  
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Figure 3.10 Treatment groups and workflow for in vivo murine model of local cancer 
recurrence following surgical resection. Female C57BL/6 mice were injected with LLC 
cells, and tumors were allowed to reach >300 mm3 before performing resection to remove 
bulk tumor. Mice were randomly assigned to one of four treatment groups and blinded 
after treatment. Body weight, days free from local recurrence, and overall survival were 
recorded/measured during the course of this study. 
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Figure 3.11 In vivo assessment of freedom from local tumor recurrence. Kaplan-Meier 
curve showing freedom from local recurrence in mice after surgical resection (*p < 
0.0001, determined using log-rank test). 
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Figure 3.12 Photomicrographs of excised tissue from implant site for (A) an unloaded 
PCL/PGC18 mesh and (B) a cisplatin-loaded PCL/PGC18 mesh, showing surrounding mild 
chronic inflammation and granulation tissue. Tumor is present deep to the unloaded 
mesh. Arrowheads represent the top and bottom boundaries of the meshes; yellow arrow 
denotes tumor tissue. Both images are 200X magnification, H&E stained sections.  
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Figure 3.13 (A) Cumulative release of cisplatin from superhydrophobic PCL/PGC-C18 
meshes pre-treated by briefly dipping meshes in 70% ethanol for 1 second, then 
transferring and submerging in PBS supplemented with 10% FBS. (B) Corresponding in 
vitro cell efficacy assay of cisplatin-loaded superhydrophobic PCL/PGC-C18 meshes 
pretreated with 70% ethanol. 
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CHAPTER 4:  Imparting Superhydrophobicity to PLGA-Based Biomaterials 
 
 
4.1 Introduction 
 
The previous chapter demonstrated the ability to generate three dimensional (3D) 
bulk superhydrophobic materials, based on PCL, for drug delivery applications using a 
combination of polymer chemistry and electrospinning, and prompted the question of 
whether such an approach is generalizable to a wider class of biomedical polymers. The 
hypothesis tested in this Chapter is that this strategy would be useful in fabricating 
superhydrophobic biomaterials based on the poly(lactic acid) and poly(glycolic acid) 
classes of copolymers. Considerable research efforts have been expended on processing 
biomedical polymers by electrospinning (Table 4.1), and generalizable strategies for 
simple modification of their physical properties could prove useful for other researchers 
and applications as well. 
Poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and poly(lactic acid-co-
glycolic acid) (PLGA) (Figure 4.1) are clinically-used polymers and prominent in 
biomedical materials research because of their non-toxicity, biodegradability, and ease of 
synthesis.157 PGA and PLGA debuted in the clinic as bioresorbable sutures in the 1960’s 
and early 1970’s, respectively.158-161 Since then, these poly(hydroxy acids) have been 
processed into a variety of other application-specific form factors, such as micro-150,162 
and nanoparticles,73,163 wafers/discs,164 meshes,165 foams,166 and films.167 Copolymers 
consisting of lactic acid and glycolic acid are particularly interesting because varying the 
monomer composition provides control over their crystallinity, mechanical strength, and 
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degradation rate(s).168,169 Other approaches for altering these properties, facilitating cell 
adhesion, or improving drug diffusion kinetics include introducing 
functionalizable154,170,171 or bioactive172 comonomers onto the polyester backbone, 
modifying the hydrophobicity/hydrophilicity via changes in surface texture and 
morphology; and also altering the form factor (fibers versus cast films) of the resulting 
material. 
In development of these materials for drug delivery applications, it is necessary to 
not only tune the rate of drug delivery, but also to control their chemical, physical, and 
mechanical properties. The work in Chapter 3 introduced the concept of using 
superhydrophobic electrospun meshes consisting of poly(ε-caprolactone) (PCL) as 
sustained drug delivery depots. PCL is a hydrophobic polyester that degrades slowly in 
the human body (~2-3 years) compared to other biodegradable polyesters such as PLGA 
(4-5 months for the 75:25 copolymer, for example).173,174 In addition to a difference in 
degradation rate, PCL and PLGA differ in their degree of crystallinity (PCL is a semi-
crystalline polymer, whereas PLGA is amorphous), and in their mechanical properties, 
with PCL being more compliant (elongation >300%)173 and PLGA being stiffer.174 
Therefore, the overall goal of this study was to demonstrate that this synergistic, 
versatile polymer chemistry and processing approach was applicable to a broad category 
of biomedical polymers for future development as superhydrophobic biomaterials. 
Specifically, superhydrophobic electrospun meshes were fabricated from PLGA doped 
with a family of novel biodegradable poly(ester carbonate) copolymers (abbreviated 
“PLA-PGC18”), and assessed the dependence on copolymer composition, percent doping, 
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and fiber size on wettability. Furthermore, we measure the mechanical properties of 
meshes, report their in vitro cytocompatibility and degradability, and assess the in vivo 
foreign body response (FBR) to meshes implanted in mice. 
 
4.2 Results & Discussion 
 
4.2.1 Synthesis of Poly(D,L-lactide-co-glycerol monostearate) 
 A family of new aliphatic poly(ester carbonate)s, poly(D,L-lactide-co-glycerol 
monostearate), were synthesized neat and in good conversion (~90%) from the racemic 
lactide monomer and 5-benzyloxy-1,3-dioxan-2-one, at 140 °C using a tin-catalyzed ring 
opening polymerization (Scheme 4.1). Monomer composition was varied to produce 
copolymers with 10, 20, 30, and 40 mole percent (mol%) glycerol carbonate (GC), which 
was confirmed using 1H NMR analysis by comparing peak integrations between the 
benzyl protecting group (–CH2) of GC and the lactide backbone (–CH2). Subsequent 
deprotection using Pd/C-catalyzed hydrogenolysis afforded a secondary alcohol, to which 
stearic acid was coupled to enhance hydrophobicity via standard DCC coupling (~90% 
yield). All final, purified polymers were collected as white powders at room temperature. 
 
4.2.2 Polymer Characterization 
Molecular weights of these C18-derivatized polymers were relatively similar (10-
17 kg/mol, Mw/Mn ~1.5) (Table 4.2), which facilitated comparison of thermal properties 
using differential scanning calorimetry (DSC). At low C18 monomer content (i.e., PLA-
PGC18 (90:10)), the copolymer is amorphous, having a glass transition (Tg) of 28 °C, and 
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no melting or crystallization event. Crystallinity increases as the C18 content increases 
from 20-40% (Table 4.3A), as evidenced by the appearance of crystallization and 
melting peaks, and increasing heats of fusion. Melting transitions (Tm) for these polymers 
also increased with increasing C18 content, which is likely due to the close, ordered 
packing of the hydrocarbon chains within the polymer, and is partially supported by the 
observation that the free hydroxyl precursor copolymer (PLA-PGCOH (60:40), also 
compound (2) on Scheme 4.1) is amorphous, with Tg = -7 °C (Table 4.3B). 
 
4.2.3 Electrospinning Microfiber Meshes 
Electrospinning is a versatile polymer processing method by which nonwoven 
nano- and microfiber meshes with high surface area and surface roughness are prepared 
from polymer melts,175 solutions,143 blended176 and immiscible mixtures,177 emulsions,178 
and even from low-molecular weight supramolecular assemblies.179 We therefore 
hypothesized that doping PLA-PGC18 copolymers into solutions (THF/DMF 7/3) of 
PLGA 75:25 (MW = 129 kg/mol, Mw/Mn = 1.6) would tune the hydrophobicity of the 
material and, through optimization, would afford three-dimensional microfiber meshes 
with superhydrophobic characteristics. 
Electrospinning was accomplished by loading these solutions into a syringe and 
syringe pump (Q = 3.0 mL/h), and applying a high voltage to the tip of the syringe needle 
as the solution was collected onto a rotating drum. The resulting microfiber meshes were 
white, flexible, and non-wetting on both their surface (Figure 4.2) and throughout their 
bulk (Figure 4.3). 
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4.2.4 Effect of Dopant Composition, Concentration & Fiber Size on Wettability 
The C18 content of the PLA-PGC18 copolymers (in terms of copolymer 
composition and doping concentration) and fiber size were varied to investigate their 
effects on the wettability of resultant electrospun meshes. The polymer dopants selected 
for electrospinning with PLGA were the PLA-PGC18 (90:10) and PLA-PGC18 (60:40) 
copolymers. SEM images of these meshes are shown in Figure 4.4 and Figure 4.5. 
While the fibers within most meshes were relatively smooth and randomly oriented, 
small-fiber meshes doped with 30% PLA-PGC18 (60:40) possessed a tertiary web-like 
structure on their surface (Figure 4.6), adding to the overall surface roughness and 
resulting in a high apparent contact angle. Fiber size was controlled by varying the total 
polymer concentration of the solutions: 30 wt% solutions resulted in small (2.5-3.5 µm) 
diameter fibers, while 40 wt% solutions resulted in large (6.5-7.5 µm) fibers. 
Indeed, both fiber size and copolymer composition (i.e., C18 content) are 
important factors in generating superhydrophobic meshes and meshes with tunable 
wettability. For example, the advancing/receding water contact angles on large-fiber 
electrospun pure PLGA were ~110°/81°. These values increased with a reduction in fiber 
size (to 120°/80° for PLGA) and/or with an increase in the percentage of copolymer 
doping, such that advancing/receding contact angles as high as ~162°/145° were obtained 
for small-fiber PLGA doped with 30% PLA-PGC18 (60:40) (Figure 4.7). Additionally, 
the difference between the advancing and receding water contact angle values (i.e., 
contact angle hysteresis) decreased once the materials transitioned from hydrophobic to 
superhydrophobic. Reducing fiber diameter enhanced mesh hydrophobicity by decreasing 
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the polymer surface fill fraction and increasing the air fraction exposed at the surface. 
Conversely, minimizing mesh surface roughness via melting the meshes into smooth 
films dramatically reduced the advancing water contact angles to 100° and lower for the 
respective compositions (Figure 4.8). 
The degree of hydrophobicity was also dependent on the composition of the 
dopant copolymer species, with an increase in hydrophobicity as the lactide:C18 ratio 
increased. In contrast, electrospun meshes doped with 30% of the free hydroxyl 
copolymer PLA-PGCOH (60:40) did not appreciably enhance mesh hydrophobicity (WCA 
≈ 120° ± 4° for 2.5-3.5 µm fibers), confirming the enhancement in hydrophobicity was 
due to the C18 moiety. 
 
4.2.5 In Vitro Biocompatibility Testing & Degradation Study 
Doped meshes were also assessed for cytocompatibility and biodegradability. Co-
incubation of PLGA or 30% doped meshes with NIH/3T3 cells showed no loss of 
viability (viability > 95%, Figure 4.9) after 24 hours, as determined using the MTS 
colorimetric viability assay and compared to that of untreated controls. The degradation 
half-life (in PBS at 37 °C) of the meshes occurred around 20-25 weeks (Figure 4.10). 
Slight differences in degradation after 25 weeks were noted. For example, the 30%-doped 
PLA-PGC18 (60:40) meshes were more resistant to degradation, losing only ~35-40% of 
their mass, compared to ~65-75% mass lost for pure PLGA meshes, after 25 weeks. The 
reduced hydrolytic degradation of PLA-PGC18-doped meshes may be due to the greater 
degree of crystallinity of the PLA-PGC18 copolymer (Table 4.3A) and the greater mole 
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fraction of PGC18 monomer units (i.e., greater number of carbonate linkages and 
hydrophobic C18 pendant groups) in these meshes. The pendant C18 is grafted to the 
polymer backbone by a hydrolyzable ester linkage, providing a mechanism for polymer 
degradation. This result is consistent with literature reports that observed slower 
degradation rates of PLGA samples having higher degrees of crystallinity,180 and also 
that polycarbonates, in general, degrade slower than polyesters.181 However, because the 
overall molar percentage of PGC18 monomers was 3× lower in the 10%-doped meshes 
and even lower for PLA-PGC18 (90:10)-doped meshes, there were no discernable 
differences in the degradation trends for the other mesh compositions. 
 
4.2.6 Critical Surface Tension Measurements on Superhydrophobic Meshes 
In addition to generating superhydrophobic meshes through the addition of PLA-
PGC18 copolymer dopants to PLGA, we investigated whether grafting other hydrophobic 
moieties on the polymer backbone can impart superhydrophobicity, such as a 
perfluroalkyl pendant chain. A poly(D,L-lactide-co-glycerol-2-2H,2H,3H,3H-
perfluorononanoate) [PLA-PGC13F (60:40)] copolymer (compound 3b in Scheme 4.1) 
was therefore synthesized in a similar manner as that of PLA-PGC18 and subsequently 
doped into a solution of PLGA and electrospun. At a 30% doping level, these 
perfluroalkyl-doped microfiber (fiber diameter = 2.5-3.5 µm) meshes exhibited contact 
angles of ~148°, which is lower than that achieved with the C18 copolymer analogue 
(~160°). The higher pure water contact angle for the PLA-PGC18 (60:40) doped PLGA 
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mesh is attributed to the greater surface roughness present on these fibers compared to 
those fibers in the PLA-PGC13F (60:40) doped PLGA mesh (Figure 4.11A). 
Considering the role of surface tension and surface energy on the wettability of 
superhydrophobic materials, wettability parameters were further explored through 
varying the surface tension of water by creating ethanol-water mixtures of known surface 
tension182 and measuring the contact angle of these droplets on the most 
superhydrophobic 30% PLA-PGC18 (60:40) and PLA-PGC13F (60:40) doped meshes. 
Despite having a higher apparent pure water contact angle, the PLA-PGC18 doped PLGA 
mesh was unable to support droplets with surface tensions < 36 mN/m, whereas the PLA-
PGC13F doped PLGA mesh maintained droplets with surface tensions as low as 23 mN/m 
(Figure 4.11B). A possible explanation for why the PLA-PGC13F doped PLGA mesh can 
support a lower surface tension liquid compared to that of the PLA-PGC18 doped PLGA 
mesh is that the smooth conformal coating present on the PLA-PGC13F doped PLGA 
fibers prevents ethanol absorption by the poly(lactic acid) better than that of the rough 
porous coating present in the PLA-PGC18 (60:40) doped PLGA meshes. 
 
4.2.7 Mechanical Properties of Electrospun PLGA-Based Superhydrophobic Meshes 
Uniaxial tensile testing on the meshes was performed to determine the effect of 
PLA-PGC18 copolymer dopant and/or fiber size on the mechanical properties (elastic 
modulus, ultimate tensile strength, and strain at failure) of the PLGA meshes (Table 4.4). 
A trend was observed of decreasing stiffness and strength with increased doping and 
reduced fiber size. However, this was not the case for meshes doped with 30% PLA-
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PGC18 (90:10), as this formulation showed enhanced mechanical strength and stiffness 
compared to that of undoped PLGA meshes. This composition also had a 20-25° increase 
in contact angle compared to that of PLGA and may be an appropriate material for 
providing enhanced hydrophobicity of PLGA without sacrificing mechanical strength, 
such as for surgical buttressing materials. 
 
4.2.8 In Vivo Foreign Body Reaction to PLGA-Based Superhydrophobic Meshes 
The in vivo biocompatibility and foreign body reaction to electrospun meshes 
were assessed 4 weeks after subcutaneous implantation in mice (Figure 4.12 and Figure 
4.13). A separate group of meshes was melted to eliminate surface roughness and 
therefore act as a non-superhydrophobic control with identical polymer composition. In 
general, meshes experienced a greater degree of tissue ingrowth (chevrons) by 
macrophages and fibroblasts compared to films, as may be expected given the greater 
degree of porosity. Nonetheless, all meshes and films (labeled with arrowheads) were 
well-tolerated in mice and showed minimal signs of fibrous encapsulation (arrows). 
Fibrous encapsulation is characteristic of a foreign body response to an implanted 
device.183 A small number of macrophages are indeed present at 4 weeks after 
implantation as part of a mild inflammatory reaction. This is to be expected as part of the 
normal host response to an implanted material that persists to this time point. The foreign 
body response to the superhydrophobic meshes (Figure 4.12) was similar to that of 
implanted PLGA meshes and smooth (i.e., non-superhydrophobic) PLGA films doped 
with 30% PLA-PGC18 (60:40) (Figure 4.13). Furthermore, these results are similar to 
 
 
 
116 
electrospun PCL meshes implanted in rats, performed by Cao, McHugh, Chew, and 
Anderson.152 Their study also examined the effect of fiber orientation (i.e., random or 
aligned) on fibrous capsule thickness and foreign body giant cell count, and they 
concluded that the fibrous architecture was capable of minimizing the FBR compared to 
that of smooth films, and that thinner fibrous capsules were observed for the aligned fiber 
meshes compared to that of the randomly oriented fiber meshes. 
 
4.3 Conclusion 
 
A series of poly(ester carbonate) copolymers based on D,L-lactide and glycerol 
were synthesized in good yield, with molecular weights of approximately 15 kg/mol. The 
ratio of glycerol to lactic acid varied from 10% to 40%, and the pendant free hydroxyl on 
glycerol was subsequently functionalized with stearic acid to impart additional 
hydrophobicity to the copolymer (PLA-PGC18). When these copolymers were added to a 
solution of PLGA at varying doping concentrations and the resulting mixtures were 
electrospun, nonwoven microfiber meshes were fabricated with varying degrees of 
hydrophobicity. Mesh wettability was controlled through selection of fiber size, the 
amount of copolymer dopant added, and/or the lactide:C18 copolymer ratio. 
Hydrophobicity, as measured by apparent advancing contact angle, varied from ~110° for 
PLGA electrospun 7-µm fiber meshes to in excess of 160° for small-fiber meshes 
containing 30 wt% PLA-PGC18 (60:40). The degradation rate for the PLGA meshes 
doped with PLA-PGC18 (60:40) is slower than that for the pure PLGA meshes, and this 
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likely due to the greater degree of crystallinity, increased hydrophobicity (i.e., C18), and 
the backbone carbonate linkages present with this polymeric mesh. 
In order to determine if this polymer chemistry approach is generalizable, stearic 
acid was replaced with a perfluoroalkyl-based carboxylic acid, which is structurally and 
chemically different. The surface of the fibers from the PLGA meshes doped with PLA-
PGC13F are smoother than those doped with PLA-PGC18, and thus these fluorinated 
meshes possess a lower apparent contact angle of ~148°. The meshes fabricated in this 
work were non-cytotoxic, as determined using the NIH/3T3 cell assay, and they do not 
elicit an adverse response when implanted in vivo. However, given the potential toxicity 
of fluorinated polymers and their breakdown products,184 additional and prolonged in 
vivo studies are warranted for the perfluoroalkyl-grafted copolymer meshes prior to any 
biomedical use. 
In summary, this Chapter described a robust and facile strategy to electrospin 
PLGA-based meshes, where the hydrophobicity of the mesh was tuned by choice of the 
polymer dopant and the electrospinning conditions. Future studies are warranted for 
evaluating these meshes, composed of known biodegradable, biocompatible aliphatic 
polyesters and poly(ester carbonate)s, for drug delivery applications where the surface 
and bulk properties are of particular importance for controlling drug release and 
cell/tissue integration, such as in a drug-eluting buttressing device that is implanted 
during surgical resection of early stage cancer. 
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4.4 Materials & Methods 
 
4.4.1 Chemicals, Reagents & Instrumentation 
All reagents were used as received without further purification or modification. 
D,L-lactide (> 96%), anhydrous toluene, stearic acid (95%), 4-dimethylaminopyridine 
(DMAP, 99%), N,N’-dicyclohexylcarbodiimide (≥ 99%), tin(II)-ethylhexanoate 
(Sn(oct)2, ~95%), and anhydrous N,N-dimethylformamide (DMF) were purchased from 
Sigma-Aldrich. Dichloromethane (DCM), methanol, and tetrahydrofuran (THF) were 
purchased from Clean Harbors, Inc. Palladium on carbon (10% on activated wood 
carbon, unreduced, ~50% water wet paste) was purchased from Strem Chemicals, Inc. 
Poly(lactide-co-glycolide), 75:25, MW 129 kg/mol (Mw/Mn = 1.6) was purchased from 
Lakeshore Biomaterials (Alabama, USA), and 2H,2H,3H,3H-perfluorononanoic acid 
(97%) was purchased from Oakwood Chemicals (South Carolina, USA). 
1H NMR and 13C NMR spectra were recorded at 93.94 kG (1H 400 MHz, 13C 100 
MHz) at ambient temperature. Proton chemical shifts are expressed in parts per million 
(ppm) relative to the residual proton solvent resonance: CDCl3 δ = 7.24. For 13C spectra, 
the centerline of the solvent signal was used as internal reference: CDCl3 δ = 77.16. 
Thermal analysis of copolymers was performed using a Q100 differential scanning 
calorimeter (TA Instruments, Delaware, USA). Thermal traces were recorded for three 
steps: (1) heating to 225 °C at 10 °C/min; (2) cooling to -75 °C at 5 °C/min; (3) heating 
to 225 °C at 10 °C/min. The second heating step (Step 3) was used to identify phase 
and/or glass transition temperatures of the polymers. Mesh topography and fiber 
morphology was characterized using a Supra V55 (Carl Zeiss, Germany) field emission 
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scanning electron microscope operated at 2 kV. Static water contact angle measurements 
to assess mesh wettability were performed using a DSA100 (Kruss, North Carolina, 
USA); droplets (4 µL) were calculated using the sessile drop fit method for ten droplets 
probed on distinct locations on the mesh. Mechanical analysis of meshes was performed 
using a 5848 Micro-tester (Instron, Massachusetts, USA) in accordance with ASTM 
standard D882 for thin plastic sheeting, using a constant strain rate of 0.05/s. 
 
4.4.2 Synthesis of Poly(D,L-lactide-co-5-benzyloxy-1,3-dioxan-2-one) (1) 
The monomer 5-benzyloxy-1,3-dioxan-2-one was synthesized according to 
literature procedure185 and recrystallized twice from DCM/Et2O prior to use. 
Polymerization (Scheme 4.1) was carried out in a 100-mL round-bottom flask on a 10 
mmol overall scale. The 5-benzyloxy-1,3-dioxan-2-one and lactide monomers were 
subjected to three vacuum-N2 purge cycles (30 minutes each) before heating to 140 °C. 
Once both solids were melted, tin(II)-ethylhexanoate (0.002 eq.), dissolved in toluene and 
subjected to the same drying procedure as outlined above, was added to the flask. 
Polymerization was carried out overnight, after which the flasks were removed from heat, 
dissolved in 50 mL dichloromethane, precipitated into methanol, and subsequently 
filtered and dried under vacuum. Conversion yields ranged from 86-96% for the various 
copolymers. 
1H NMR (CDCl3): 1.52-1.62 (m, 6H, CH3), 3.81-3.90 (broad, 1H, O-CH), 4.13-
4.41 (m, 4H, OCH2), 4.58-4.68 (s, 2H, PhCH2), 5.08-5.25 (m, 2H, OCH), 7.30-7.36 (m, 
5H, aromatic). Analysis of 1H NMR integrations provided overall polymer composition 
(i.e, lactide to glycerol carbonate mole percent). 
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4.4.3 Synthesis of Poly(D,L-lactide-co-5-hydroxy-1,3-dioxan-2-one) (2) 
Removal of the benzyl protecting group from compound 1 was achieved using 
Pd/C-catalyzed hydrogenolysis in THF at room temperature for 24 hours. The solution 
was filtered through diatomaceous earth (Celite® 545), concentrated, precipitated into 
methanol, and dried under vacuum. 1H NMR confirmed complete deprotection/de-
benzylation via the disappearance of the benzyl and aromatic protons (occurring at 4.58-
4.68 and 7.30-7.36 ppm, respectively). 
 
4.4.4 Synthesis of Poly(D,L-lactide-co-glycerol monostearate) (3a) 
The polymer (2) was first dissolved in DCM, and stearic acid (1.5 eq.) was 
coupled to the free secondary alcohol of the glycerol monomer moiety using DCC (2.0 
eq.) and a catalytic amount of DMAP. The solution was filtered, concentrated, and 
precipitated into an excess of cold methanol; then filtered and dried under vacuum. 
Overall yields ranged from 76-88%. 
1H NMR (CDCl3): 0.85-0.90 (t, 3H, CH3), 1.20-1.34 (m, 2H, CH2), 1.48-1.65 (m, 
6H, CH3), 2.28-2.37 (m, 1H, OCH), 4.14-4.48 (m, 4H, OCH2), 5.11-5.31 (m, 2H, OCH). 
13C NMR (CDCl3): 14.09, 16.61, 16.17, 16.70, 16.76, 22.65, 24.69, 25.42, 29.03, 
29.24, 29.33, 29.44, 29.62, 29.66, 31.89, 33.97, 34.88, 62.81, 65.71, 68.19, 68.96, 69.06, 
69.12, 71.63, 154.36, 169.57, 172.69, 172.76. 
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4.4.5 Synthesis of Poly(D,L-lactide-co-glycerol perfluorononanoate) (3b) 
Coupling of 2H,2H,3H,3H-perfluorononanoic acid onto the hydroxyl group of 
polymer 2 was accomplished using identical reaction conditions as that for the C18 
coupling described above, but reacted for 48 hours. The dark-brown reaction mixture was 
filtered to remove DCU, concentrated, and then precipitated five times from cold 
methanol and once from hexanes. The resulting polymer was a slight off-white solid 
obtained in 65% yield. 
1H NMR (CDCl3): 1.48-1.63 (m, 6H, CH3), 2.43-2.52 (m, 1H, OCH), 2.65-2.71 
(m, 4H, CH2), 4.25-4.44 (m, 4H, OCH2), 4.96-5.35 (m, 2H, OCH). 
19F NMR (CDCl3): -81.17 (3F), -115.13 (2F), -122.29 (2F), -123.26 (2F), -123.89 
(2F), -126.54 (2F). 
 
4.4.6 Electrospinning PLGA-Based Superhydrophobic Meshes 
PLGA served as the major constituent of polymer blends due to its high molecular 
weight and consequent high viscosity to afford chain entanglements, and hence, the 
ability to be electrospun. All polymers were dissolved in a mixture of THF/DMF (7/3) 
and thoroughly mixed before loading into a 10-mL glass syringe. The syringe was placed 
into a syringe pump and immediately electrospun from the tip of a 20 AWG blunt needle 
at a flow rate of 3 mL/h and applied voltage of 7.5-15 kV. The resulting fiber jet was 
collected onto a grounded rotating and translating aluminum drum to collect a large mesh 
of uniform thickness. Meshes were allowed to air-dry at room temperature overnight 
before performing subsequent characterization. 
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4.4.7 Cytocompatibility Testing of Electrospun Meshes 
NIH/3T3 mouse fibroblast cells were maintained in DMEM supplemented with 
10% newborn calf serum, 100 U/mL penicillin and 100 µg/mL streptomycin, and 
incubated in a humidified, 5% CO2, 37 °C environment. Cells were harvested from 25 
cm2 cell culture flasks, seeded into 24-well plates at a density of 4,000 cells/well, and 
allowed to adhere overnight. Prior to exposure to cells, electrospun meshes were cut in 
squares (0.5 cm x 0.5 cm) sterilized under ultraviolet (UV) light, and loaded in transwell 
plates. Transwells were then added to the cell-containing 24-well plates and incubated for 
24 hours. Viability was assessed using an MTS colorimetric assay and represented as the 
percentage of viable cells as compared to cells not co-incubated with mesh. 
 
4.4.8 Degradation Studies 
Meshes were cut to ~1 cm2 squares and weighed, followed by UV-sterilization 
overnight. The meshes were then submerged in 50 mL sterile PBS and incubated at 37 °C 
under aseptic conditions. PBS was discarded monthly and replaced with fresh, sterile 
PBS. After 8 and 25 weeks’ incubation, the meshes were carefully removed and rinsed in 
distilled water, and allowed to dry for 48 hours. Meshes were subsequently weighed to 
determine the percentage mass lost as a function of incubation duration. 
 
4.4.9 In Vivo Foreign Body Response in Mice 
Meshes were processed into their film counterparts by heating until the fibers 
coalesced into a homogenous, viscous transparent film that hardened upon cooling. 
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Animal experiments/protocol were approved by the Institutional Animal Care and Use 
Committee of Dana Farber Cancer Institute. The skin of the mice was shaved and 
aseptically prepared followed by a 0.5-cm incision under isoflurane (1.0%-1.5%) 
inhalation anesthesia. A subcutaneous pocket was made by blunt dissection. Films and 
meshes were cut to 0.6 x 0.6 cm2 squares, sterilized by UV irradiation, and then randomly 
implanted on the upper or lower back of C57BL/6 female mice (Jackson Laboratory, Bar 
Harbor, ME), such that each mouse received two different film/mesh types. After closure 
of the incision with 5-0 polypropylene sutures, mice were monitored until full recovery 
from anesthesia. After 4 weeks’ implantation, the meshes and surrounding tissue were 
carefully harvested after euthanasia, and cross sections were prepared by paraffin 
embedding and H&E staining. Optical microscopy was performed on an Olympus BX41 
microscope with an attached Olympus DP70 digital camera using automated exposure 
setup. 
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124 
Table 4.1 Examples of synthetic biomedical polymers that have been electrospun, 
with accompanying references. 
Electrospun Synthetic Polymers: Reference(s): 
Poly(lactide-co-glycolide) 160,165,186-191 
Polyglycolide 191,192 
Poly(lactide-co-caprolactone) 193-196 
Polycaprolactone 136,152,197-204 
Polylactide 191,205 
Poly(vinyl alcohol) 206-209 
Poly(ethylene glycol)/block copolymers 210,211 
Poly(ester urethane)s 212-216 
Poly(trimethylene carbonate) 217 
Poly(dimethyl siloxane) 218,219 
Poly(ethylene-co-vinyl acetate) 220 
Poly(vinylpyrrolidone) 221 
Polyamide(s) 222-224 
Polyhydroxybutyrate 225,226 
Polyphosphazene(s) 227,228 
Poly(propylene carbonate) 229-231 
Polyethyleneimine 232,233 
Poly(γ-glutamic acid) 234 
Silicate 235,236 
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Table 4.2 Monomer composition and molecular weight determination of synthesized 
poly(lactide-co-glycerol monostearate) (PLA-PGC18) copolymers. 
Copolymera Conversion (%)  Lactideb Glycerolb Mn (g/mol)c Mw/Mnd 
 
PLA-PGC18 
(90:10) 
 
 
92 
  
89 
 
11 
 
12,500 
 
1.5 
PLA-PGC18 
(80:20) 
 
96  78 23 11,000 1.5 
PLA-PGC18 
(70:30) 
 
90  66 34 17,300 1.5 
PLA-PGC18 
(60:40) 
86  54 47 13,200 1.6 
 
aRatios in parentheses denote the intended/theoretical ratio of the corresponding 
monomers; bMole %, as determined by 1H NMR; cAs determined by size exclusion 
chromatography (THF, 1.0 mL/min; polystyrene standards); Mn = number average 
molecular weight; dMw/Mn = dispersity. 
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Table 4.3 (A) Thermal properties of synthesized poly(lactide-co-glycerol 
monostearate) (PLA-PGC18) copolymers, determined using differential scanning 
calorimetry (DSC). (B) Thermal properties of hydroxyl- and perfluoroalkyl-based 
copolymer derivatives. 
A 
Copolymer Tg (°C)a Tm (°C)b Tc (°C)c ∆Hf (J/g)d 
 
PLA-PGC18 
(90:10) 
28 - - - 
 
PLA-PGC18 
(80:20) 
17 33 11 3.0 
 
PLA-PGC18 
(70:30) 
* 40 17 23 
 
PLA-PGC18 
(60:40) 
* 43 27 32 
 
B 
 
 
 
aTg = glass transition temperature; 
bTm = melting temperature; 
cTc = crystallization 
temperature; d∆Hf  = heat of fusion. *No Tg was observed for these semicrystalline 
polymers over the temperature range -75 – 225 °C.  
Copolymer Tg (°C)a Tm (°C)b Tc (°C)c ∆Hf (J/g)d 
 
PLA-PGCOH 
(60:40) 
-7 - - - 
 
PLA-PGC13F 
(60:40) 
29 - - - 
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Table 4.4 Mechanical (tensile) properties of electrospun microfiber meshes 
composed of PLGA and PLGA doped with PLA-PGC18 copolymers. 
Copolymer 
dopant Doping (%) Fiber sizea E (MPa)b UTS (MPa)c ε(break)d (%) 
PLA-PGC18 
 (90:10) 
10 large 166.2 ± 20 6.3 ± 0.3 12 
10 small 139.4 ± 15 2.9 ± 0.3 - 
30 large 90.9 ± 3.4 2.4 ± 0.6 - 
30 small 90.4 ± 5.5 3.0 ± 0.1 - 
  
PLA-PGC18 
 (60:40) 
10 large 40.3 ± 8.9 0.8 ± 0.1 1.9 
10 small 46.5 ± 11 1.7 ± 0.2 31 
30 large 10.1 ± 4.4 0.3 ± 0.1 8.7 
30 small 1.1 ± 0.4 0.1 ± 0.01 - 
      
PLGA 
(undoped) 
0 
0 
large 
small 
84.9 ± 15 
63.6 ± 11 
2.6 ± 0.4 
2.5 ± 0.4 
- 
- 
 
aLarge fibers: 6.5-7.5 µm; small fibers: 2.5-3.5 µm;  bE = elastic (Young’s) modulus; 
cUTS = ultimate tensile strength; dstrain (ε) at failure. 
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Scheme 4.1 Synthesis of polylactide-based poly(ester carbonate) copolymers. 
Monomer mole ratios (m and n) were varied to generate a family of copolymers with 
different monomer composition.  
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Figure 4.1 Molecular structures of (A) poly(D,L-lactic acid) (B) poly(glycolic acid) 
(C) poly(D,L-lactide-co-glycolide). 
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Figure 4.2 An electrospun superhydrophobic PLGA mesh doped with 30% PLA-
PGC18 (60:40). (A) Photograph of mesh, (B) water droplet on mesh surface showing a 
contact angle of 160°. 
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Figure 4.3 Demonstration of bulk superhydrophobicity of a superhydrophobic mesh. 
A non-wetted mesh, full of entrapped air, floats on water (left, colored green with dye to 
increase contrast), while an ethanol-wetted mesh placed in water absorbs it and sinks to 
the bottom (right). Dry and wetted meshes removed from the water are white and green, 
respectively (scale bar = 1 cm).  
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Figure 4.4 SEM images of electrospun small- and large-fiber PLGA-based meshes 
(left and right, respectively). Small fibers were 2.5-3.5 µm in diameter, while large fibers 
were 6.5-7.5 µm in diameter. (A) Undoped PLGA meshes. (B) PLGA meshes doped with 
10% PLA-PGC18 (90:10). (C) PLGA meshes doped with 30% PLA-PGC18 (90:10). Scale 
bars = 10 µm.   
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Figure 4.5 SEM images of electrospun small- and large-fiber PLGA-based meshes 
(left and right, respectively). Small fibers were 2.5-3.5 µm in diameter, while large fibers 
were 6.5-7.5 µm in diameter. (A) PLGA meshes doped with 10% PLA-PGC18 (60:40). 
(B) PLGA meshes doped with 30% PLA-PGC18 (60:40). Scale bars = 10 µm. 
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Figure 4.6 SEM of a superhydrophobic mesh with high surface roughness. (A) Low-
magnification SEM of mesh (scale bar = 10 µm). (B) High-magnification SEM, showing 
a tertiary web-like structure on the surface of the fibers (scale bar = 2 µm). 
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Figure 4.7 Influence of fiber size, copolymer dopant species, and percent doping on 
hydrophobicity of PLGA-based microfiber meshes (PLGA, white; PLA-PGC18 (90:10), 
blue; PLA-PGC18 (60:40), orange). Bars with numbers above represent the advancing 
contact angle; bars without numbers above represent the receding contact angle. Error 
bars represent standard deviation (n = 10). 
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Figure 4.8 Advancing and receding water contact angles on smooth films composed 
of PLGA or a blend of PLGA with corresponding PLA-based poly(ester carbonate)s. 
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Figure 4.9 In vitro cytocompatibility transwell assay of cells co-incubated with 
PLGA and 30%-doped PLGA meshes (n = 4). Error bars represent standard deviation. 
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Figure 4.10 Degradation behavior of PLGA and doped PLGA meshes after incubating 
for 8 (grey) and 25 (black) weeks in PBS at 37 °C. Ratios correspond to lactide:glycerol 
carbonate monomer content. Small- and large-diameter fiber PLGA and doped-PLGA 
meshes were tested and are shown as solid and hashed bars, respectively; percentages 
correspond to dopant copolymer concentration (w/w). Error bars represent standard 
deviation. 
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Figure 4.11 Comparison of surface roughness by SEM and critical surface tension 
measurements. (A) High-magnification SEM of small-fiber PLGA mesh doped with 30% 
PLA-PGC18 (60:40) (top), showing high surface roughness compared to fibers fabricated 
from small fiber PLGA meshes doped with 30% PLA-PGC13F (60:40) (bottom), which 
has smooth fibers. (B) Contact angle as a function of surface tension for PLGA meshes 
doped with 30% PLA-PGC18 (60:40) and PLA-PGC13F (60:40). Fiber size was 2.5-3.5 
µm for both meshes (scale bar = 1 µm; error bars represent ± SD for 10 droplet 
measurements). 
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Figure 4.12 Histological (H&E) specimens of harvested subcutaneous mouse tissue 
surrounding implanted superhydrophobic meshes after 4 weeks. (A) Superhydrophobic 
PLGA + 30% PLA-PGC18 (60:40) mesh at 10X magnification, (B) 40X image, (C) 
superhydrophobic PLGA + 30% PLA-PGC13F (60:40) mesh at 10X magnification, (D) 
40X image. Arrows indicate the edge of the mesh where the fibrous capsule has formed; 
arrowheads show the film boundaries; chevrons indicate the presence of cell ingrowth. 
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Figure 4.13 Histological (H&E) specimens of harvested subcutaneous mouse tissue 
surrounding implanted non-superhydrophobic meshes and films after 4 weeks. (A) PLGA 
mesh at 10X magnification, (B) 40X image, (C) PLGA film at 10X magnification, (D) 
40X image, (E) non-superhydrophobic PLGA + 30% PLA-PGC18 (60:40) film/melted 
mesh at 10X magnification, (F) 40X image. Arrows indicate the edge of the mesh where 
the fibrous capsule has formed; arrowheads show the film boundaries; chevrons indicate 
the presence of cell ingrowth.  
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CHAPTER 5:  Exploitation of Crack Propagation Failure Modes for Composite 
Drug Delivery Materials 
 
 
5.1 Introduction 
 
As demonstrated in the previous two chapters, the design of superhydrophobic 
materials is useful for sustained-release of chemotherapy in the prevention of local cancer 
recurrence—and further, this strategy of combining polymer chemistry and processing 
(via electrospinning) to construct superhydrophobic materials is also applicable to a 
variety of commonly used biomedical polymers. However, there are instances where the 
triggered release of drugs from these depots may be desired, such as in interventional 
cardiology or injury. That the superhydrophobic design element is critical for preventing 
the burst release of entrapped agents presents an opportunity to design a system where the 
use of tension acts as a drug release stimulus by altering and/or destroying the 
superhydrophobic effect. Successful attempts to alter the wettability of superhydrophobic 
surfaces through the use of tension have been reported by several researchers, although 
their efforts stop short of demonstrating applications in drug delivery. These reports 
generally rely on imposing mechanical strain on rough surface topologies to disrupt the 
superhydrophobic effect. This Chapter therefore focuses on generating a 
‘mechanoresponsive’ superhydrophobic system that is amenable to drug delivery 
applications. 
Mechanoresponsive polymeric materials are of significant interest as functional 
design elements in self-healing materials,237-240 sensors and electronics,241-244 and 
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biology/medicine.111,112,245-247 Specifically, biomedical materials incorporating 
mechanoresponsive elements are highly desirable and take into consideration the 
dynamic nature of the human body and its subjection to routine micro- and macroscopic 
forces during normal physical activity, growth and development, and injury.248-250 In 
addition, implanted medical devices also experience many of these forces, and even exert 
their own mechanical forces during use (e.g., interventional stenting and balloon 
angioplasty).251,252 Consequently, mechanoresponsive materials are actively being 
developed that respond to mechanical stimuli such as compression63,65-67, tension,69,70,253 
shear,73 or ultrasound.254-256 
This Chapter’s approach to designing functional mechanoresponsive materials 
involves using crack propagation failure modes of composite materials as graded drug 
release stimuli. It is hypothesized that crack formation can be initiated and propagated 
through superhydrophobic coatings on a multilayered drug delivery system using applied 
tension, with consequent device wetting and drug release in aqueous environments. 
Herein, the fabrication of a multilayered electrosprayed polymeric device is reported. 
Additionally demonstrated are the entrapment and subsequent release of both hydrophilic 
and lipophilic agents under various applied strains, an analysis of the crack propagation 
mechanism with determination of the fracture toughness and critical strain energy release 
rate, and the in vitro tension-mediated delivery of cisplatin and 7-ethyl-10-
hydroxycamptothecin (SN-38) to cancer cells. 
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5.2 Results & Discussion 
 
5.2.1 Fabrication & Characterization of Tension-Responsive Devices 
From a design perspective, the device consists of a hydrophilic mesh core 
(containing an active agent) encased by two superhydrophobic coatings that resist wetting, 
causing a mismatch in mechanical properties. Constructing the core from a stronger 
substrate than the coatings ensures mechanical failure of the coatings in the presence of 
applied tension, with crack propagation resulting in rapid water infiltration and release of 
the entrapped agent. The absorbent cellulose/polyester core is rendered water-impermeable 
by electrospraying its entire surface with a low surface energy polymer blend. 
Electrospraying was selected to produce superhydrophobic materials, as opposed to 
micropatterning/micro-texturing,257 solvent-induced polymer crystallization,258 layer-by-
layer deposition,151 and electrospinning,137,259,260 due to its ability to generate coatings of 
interconnected, hydrophobic micro- and nanoparticles on otherwise hydrophilic bulk 
materials, and because it is an industrial scalable technique.261 The combination of low 
surface energy from the blend of two biodegradable, biocompatible polymers 
(polycaprolactone (PCL) and poly(glycerol monostearate-co-caprolactone) (PGC-C18, 
Figure 5.1A), and high surface roughness from electrospraying, are requisites for eliciting 
superhydrophobicity, which is defined as a surface possessing advancing water contact 
angles > 150° with low contact angle hysteresis.262,263 Cross-sectional SEM (Figure 5.1B) 
shows the three layers of the device, with coatings composed of interconnected particles of 
2-7 µm diameter (Figure 5.2), and exhibiting advancing water contact angles approaching 
170°, as measured using goniometry (Figure 5.3). Without these superhydrophobic 
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coatings, the hydrophilic core rapidly absorbs water and organic solvents (dichloromethane, 
hexanes, methanol, and dimethylformamide). This indiscriminate absorbency permits a 
variety of molecular agents to be loaded and studied. 
 
5.2.2 Tension-Responsive Release Studies of a Model Hydrophilic Drug 
The tension-responsive release of an agent from these multilayered devices is 
readily visualized using hydrophilic green dye, and quantified by UV-Vis 
spectrophotometry (λmax = 630 nm). Dye-loaded meshes, initially green, progressively 
become white as the 100 µm-thick coating is deposited, and finished devices do not wet 
when submerged in simulated biological fluid (PBS w/ 10% fetal bovine serum) for 
prolonged durations (> 24 hours). When subjected to tension, however, disruption of this 
otherwise stable air barrier occurs via coating fracture and causes subsequent dye efflux. 
Importantly, dye release rates are controlled by the magnitude of applied strain input 
(Figure 5.4). All release aliquot concentrations after application of strain are significantly 
higher than those measured in the absence of strain, and aliquot concentrations for ε = 0.1 
and ε = 0.3 are significantly different from ε = 1.0 after 5 minutes and 10 minutes, 
respectively (ANOVA, p < 0.05). Coatings that are merely hydrophobic (PCL, θadv = 
119°) do not prevent drug release in the absence of tension, confirming the necessity of 
superhydrophobic coatings for this system. Water infiltration upon coating fracture is also 
observed using contrast-enhanced microcomputed tomography (µCT) by submerging in a 
solution of PBS supplemented with 10% fetal bovine serum and the CT contrast agent 
iodixanol, and subjecting the devices to tension (ε = 1.0). As shown in Figure 5.5, µCT 
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attenuation between un-stretched (Figure 5.5A) and stretched (Figure 5.5B) devices is 
noticeably different due to the compromised superhydrophobic coating and consequent 
core hydration after applying tension. Because bulk wetting of the coating does not occur, 
as visualized by the minimal attenuation at the outer layers of the device (boundaries 
denoted by arrowheads), the mechanism of release is attributed to core hydration by 
water infiltrating through the fractured superhydrophobic coatings. 
 
5.2.3 Analysis of Crack Propagation within Tension-Responsive Devices 
Modulating drug release rates by varying strain input is a result of crack 
formation and propagation through the superhydrophobic coatings, whose mechanism is 
further studied using fracture image analysis and tensile testing. The sequence of images 
in Figure 5.6 shows the effect of increasing tensile strain (ε = 0 to 1.0) to initiate release. 
Macroscopic crack initiation occurs at strain magnitudes of ~0.3 (Figure 5.6A), followed 
by propagation and additional crack formation as strain increases. As shown in Figure 
5.7A and Figure 5.7B, the number of cracks increase at first and then begin to decrease 
as the cracks merge with one another, resulting in an increase in mean crack area as strain 
increases. As a result, there is more exposed surface area of the core, resulting in faster 
release rates. These fracture patterns are reminiscent of those found in thin films adhered 
to rigid, deformable substrates,264 which consist of periodic parallel cracks formed 
perpendicular to the direction of applied strain. Mechanical analysis in accordance with 
ASTM Standard D 5049-99, using a notched polydimethylsiloxane (PDMS) substrate 
analog of the mesh system (Figure 5.8), estimates plane-strain fracture toughness (KIc) 
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and critical strain energy release rate (GIc) at 0.0103 ± 0.00165 MPa·m
1/2 and 1.253 ± 
0.595 N·mm-1, respectively. These KIc and GIc values represent a limit of fracture 
resistance in terms of applied stress and strain of the coating, respectively. Using the KIc 
and GIc values, and accounting for the volume fraction of the two materials, the Young’s 
modulus (E) of the coating is estimated through the relation 
𝐸 =
𝐾𝐼𝑐
2 (1− 𝜐2)
𝐺𝐼𝑐
  ,              (Eq. 1) 
resulting in a value of 0.0303 ± 0.014 MPa—two orders of magnitude lower than the core 
substrate. Together with KIc and GIc, E of the coating and substrate describe the favorable 
conditions for forming cracks and their subsequent morphology,265,266 and will aid in the 
design considerations for future tension responsive systems. 
 
5.2.4 Application of Tension-Responsive Drug Delivery to Cancer Treatment 
An area where mechanoresponsive drug delivery may have utility is in the 
treatment of esophageal cancer. Esophageal cancer is the sixth deadliest cancer 
worldwide with a 5-year survival rate of 17.5%.114,267 Patients typically suffer from 
difficulty swallowing both solid and liquid food due to tumor ingrowth. In order to 
mitigate symptoms, esophageal stents are often used to keep the esophagus open to allow 
better intake of nutrients, increasing comfort and quality of life. This system may be 
easily integrated around such an esophageal stent, where the expansion could serve as a 
mechanical cue to release chemotherapy agents from the device. 
As a first step towards this application, two chemotherapeutic agents (cisplatin or 
SN-38) are entrapped within the core of the multilayer tension responsive device and 
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evaluated against the OE33 human esophageal cancer cell line. These two 
chemotherapeutic agents differ in their hydrophilicity and lipophilicity, with cisplatin 
being hydrophilic and SN-38 being lipophilic. As shown in Figure 5.9A, the release 
profile for cisplatin is similar to the hydrophilic dye, and statistically significant 
differences in percent release from the control (ε = 0) are achieved starting at 2 minutes at 
ε = 1.0 and after 40 minutes for both ε = 0.1 and 0.3. Statistically significant differences 
in cell viability (i.e., dose response) are achieved by varying the applied strain magnitude 
of cisplatin-loaded devices from 0 (control), 0.3, and 1.0 after 30 minutes and 5 minutes, 
respectively (Figure 5.9B). Likewise, strain-dependent release rates are observed with 
SN-38-loaded devices, but over a longer duration because SN-38 is lipophilic (Figure 
5.10A). Statistically significant increases of SN-38 release occur after 0.5 hour and 2.5 
hours between the control and ε = 1.0 or ε = 0.5, respectively. Similar strain-dependent 
dose-response behavior is observed using SN-38-loaded devices subjected to strain 
magnitudes of 0, 0.5, and 1.0 after 0.25 hour (Figure 5.10B). All tests were conducted 
with ANOVA one-way (p < 0.05). Also noteworthy is that release aliquots from drug-
loaded devices elicit efficacy (cytotoxicity) against OE33 cells only after applying strain. 
 
5.2.5 Relation to Others’ Reports on Tension-Responsive Superhydrophobic Materials 
While selective wetting of superhydrophobic materials in response to chemical, 
environmental, and physical stimuli is an active area of functional materials 
research,156,256,268,269 the tension-induced wetting of a superhydrophobic material via 
crack propagation departs from previously reported approaches. For example Zhang et 
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al.47 used a triangular polyamide mesh to reversibly transition from superhydrophobic to 
superhydrophilic (i.e., wetting) states using equibiaxial strains greater than 120%. They 
explained this wetting transition was due to an increase in the average side length of the 
triangular net-like pores, which substantially reduced surface roughness, thus overcoming 
the droplet surface tension and causing its collapse. Choi and coworkers45 demonstrated a 
similar approach using absorbent fabrics that were rendered superomniphobic by dip-
coating in a solution of fluorodecyl polyhedral oligomeric silsesquioxanes. Wetting of 
these omniphobic surfaces by a variety of non-polar solvents was achieved using 
equibiaxial strains greater than ~20%, depending on droplet surface tension. These 
critical strain values helped identify governing parameters of surface roughness (such as 
critical spacing ratio, robustness factor, and reentrant curvature) responsible for 
maintaining the non-wetting state in response to biaxial tension. In contrast, Wang, Shi, 
Pan, Yang, Peng, Zong, Shi, and Yu developed superhydrophobic coatings templated 
from polyaniline hydrogels that were highly resistant to uniaxial and biaxial strain-
induced wetting.270 While these approaches provide a basis of altering wettability by 
changing microscale surface features, this study employs a more macroscopic approach 
to altering wettability—specifically, by introducing fractures within composite materials. 
 
5.3 Conclusion 
 
In conclusion, the fabrication, characterization, and evaluation of a tension-
responsive drug delivery system is described. The superhydrophobic microparticle 
coatings are applied to core substrates (cellulose/polyester or PDMS) using a facile and 
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scalable electrospraying process, which provides flexibility in substrate choice and the 
potential to incorporate these mechanoresponsive systems onto existing medical devices 
to enhance their current functionality. The key design feature responsible for the tension-
triggered release of entrapped agents is facilitating crack initiation and propagation 
within these coatings due to their mismatch in mechanical properties with the core. The 
device is amenable to delivery of both lipophilic and hydrophilic agents, suggesting 
widespread utility for a number of drug delivery applications where mechanical force, 
such as tensile strain or device expansion, are commonly experienced. 
 
5.4 Materials & Methods 
 
5.4.1 Materials & Reagents 
All reagents were used without further purification/modification. 
Dichloromethane (DCM, reagent grade), ε-caprolactone (97%), tin(II)-ethylhexanoate 
(~95%,), N,N‘-dicyclohexylcarbodiimide (DCC, ≥ 99%), stearic acid (95%), SN-38 
(98%), cisplatin (≥ 99.9%), anhydrous toluene, polycaprolactone (Mw = 45 kg/mol), 
anhydrous dimethylformamide (DMF, 99.8%), and OE33 cells were purchased from 
Sigma-Aldrich. Reagent grade chloroform and methanol were purchased through Clean 
Harbors, Inc. Fetal bovine serum (FBS) was purchased from Atlanta Biologicals. 
Palladium on carbon catalyst (Pd/C, 10% on activated wood carbon, unreduced, ~50% 
water wet paste) was purchased from Strem Chemicals, Inc. Silicone elastomer 
(SYLGARD 184) was purchased from Dow-Corning. 
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5.4.2 Polymer Synthesis 
Poly(glycerol carbonate-co-ε-caprolactone) (PGC),  the precursor polymer, was 
prepared as previously described in Chapter 3.154 Briefly, the two monomers ε-
caprolactone and 5-benzyloxy-1,3-dioxan-2-one were added 4:1 (mol) to a dried 100-mL 
round bottom flask and heated to 140 °C. Tin (II) ethylhexanoate (0.002 eq.), dissolved in 
~150 µL toluene was then added under nitrogen, and the reaction was allowed to proceed 
18 hours. The polymer product was dissolved in DCM, precipitated into methanol, and 
converted to the functionalizable hydroxyl-bearing copolymer through Pd/C 
hydrogenation, followed by filtration through diatomaceous earth. Stearic acid was then 
grafted to the hydroxyl using standard DCC coupling in DCM for 18 hours under 
nitrogen. The final copolymer, poly(glycerol monostearate-co-ε-caprolactone) (PGC-C18) 
(1:4 comonomer ratio, Mw = 30 kg·mol
-1), was purified by three repeated precipitations in 
cold methanol. 
 
5.4.3 Device Fabrication 
The core materials, composed of non-woven hydroentangled cellulose and 
polyester blended meshes (Texwipe), were cut into 50 mm x 30 mm strips. Drug 
solutions of cisplatin and SN-38 were prepared at a concentration of 25 mg/mL in 
anhydrous DMF, and 1 mg/mL in methanol:chloroform (1:1) with 20 µL DMF, 
respectively. Dye or drug solutions were wicked into the core by pipetting 50 µL 
throughout its surface, followed by air-drying for 24 hours. Loaded core substrates were 
adhered to double-sided conductive copper tape and affixed to a rotating, grounded 
 
 
 
152 
aluminum drum to provide even surface coverage of the coatings. Electrospraying was 
then carried out at 20 kV from a 10% (w/v) solution blend of PGC-C18 and PCL (1:1), or 
PCL in chloroform (Q = 5 mL/h, tip-to-collector distances of 10 cm and 15 cm, 
respectively, 30-50% relative humidity). After coating one side and allowing to dry 
overnight, the subsequent sides were electrosprayed using the same conditions. 
 
5.4.4 Characterization & Instrumentation 
Contact angle measurements (apparent, advancing, and receding) were conducted 
with deionized water on a Kruss DSA100 goniometer. Samples for scanning electron 
microscopy (SEM) were mounted on aluminum sample stubs with double-sided copper 
tape and sputtercoated with 5 nm of gold-palladium. Samples were imaged with a Zeiss 
SUPRA 40VP field emission SEM with an accelerating voltage of 2 kV, and particle size 
was analyzed with ImageJ (National Institutes of Health). The integrity and coverage of 
coatings was confirmed by probing the entire surface with a hanging droplet of deionized 
water. Mechanical (tensile) measurements were obtained using an Instron 5848 
Microtester with a 100N load cell. 
Microcomputed tomography studies were performed by submerging devices in a 
solution (80 mgI/mL) of iodixanol (GE Healthcare) for 5 minutes. While submerged, 
devices were elongated to a strain magnitude of 1.0. Water infiltration (i.e., contrast agent 
solution) was measured using a Scanco Medical µCT40 imaging system as previously 
described,156 using an isotropic voxel resolution of 36 µm3, 70 kVP tube voltage, 114 µA 
current, and 300 ms integration time. Image slices were converted into the standard 
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image format (DICOM) using proprietary software from Scanco Medical. Data were 
reconstructed and analyzed using a commercial image processing software (AnalyzeTM, 
Mayo Clinic). 
 
5.4.5 Tension-Mediated Release Studies 
Devices were glued between two pieces of foam tape, placed between the grips of 
a tensile tester, and submerged in 300 mL of PBS with 10% v/v FBS (dye-loaded 
devices) or RPMI cell culture medium with 10% v/v FBS (for drug-loaded devices). A 
magnetic stir bar was used to ensure thorough mixing during these studies. Devices were 
elongated at rate of 2 mm/s until reaching the desired strain magnitude, and aliquots (2 
mL) were withdrawn from the bath at predetermined timepoints. Dye concentrations in 
release media (PBS + 10% FBS) were measured using a HP 8453 UV-Vis 
spectrophotometer at 630 nm and compared to a standard curve. The concentration of 
cisplatin in release media (RPMI + 10% FBS) at each time point was measured using a 
Varian AA240Z atomic absorption spectrophotometer (265.5 nm) with pyrolitic carbon-
coated graphite tubes and Zeeman background correction.271 SN-38 aliquots were mixed 
1:3 with 20 mM borate buffer (pH 9), to convert all of the SN-38 to its carboxylate form, 
and their concentrations determined using a PTI QuantaMasterTM 300 fluorimeter (λex = 
380 nm, λem = 550 nm) and compared to a standard curve. 
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5.4.6 Fracture & Mechanical Analysis 
Crack propagation patterns were recorded on high definition video during 
elongation/tensile tests. PDMS samples were prepared by mixing (10:1) elastomer base 
with curing agent, and allowed to cure for 48 hours at room temperature. Both sides of 
the compact tension specimen were sputtercoated with gold to enhance conductivity for 
electrospraying. Control samples were fabricated with identical geometry and 
sputtercoating, but were not subsequently electrosprayed. Compact tension specimens 
were elongated at 2 mm/s, in accordance with ASTM Standard D 5049-99. KIc and GIc 
were calculated as described in text for samples with and without electrosprayed coatings 
(n = 3) from force-displacement curves, and normalized for volume fraction of the 
electrosprayed coating in relation to the PDMS substrate (0.85 PDMS:0.15 
electrosprayed coating). 
 
5.4.7 Cell Culture/In Vitro Assays 
OE33 cells were maintained in RPMI + 10% FBS in a humidified incubator with 
5% CO2. Cells were seeded in 12-well plates at a density of 2 × 10
4 cells/well and 
allowed to adhere for 24 hours. Aliquots of release media (1 mL) were sterile-filtered 
through 0.22-µm membranes and pre-incubated at 37 °C and 5% CO2 for 30 minutes to 
equilibrate pH. Medium in cell-containing wells was then aspirated and replaced with 
pre-incubated aliquots. The cells were further incubated for 96 or 72 hours (SN-38 and 
cisplatin, respectively). Cell viability was measured using the tetrazolium-based 
colorimetric MTS assay (absorbance read at 492 nm). 
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Figure 5.1 Fabrication schematic, concept, and elements of a tension-responsive drug 
delivery system. (A) The drug-loaded reservoir/core material (green) is protected from 
burst release and water absorption using electrosprayed superhydrophobic microparticle 
barrier coatings (yellow layers). (B) SEM cross-section of device showing the core 
between two microparticle coatings.  
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Figure 5.2 SEM of superhydrophobic microparticle coatings used to construct the 
mechanoresponsive drug delivery system (scale bar = 10 µm). 
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Figure 5.3 Advancing water contact angle measurements on electrosprayed 
microparticle coatings. (A) Hydrophobic coating composed of pure PCL (ACA = 119°, 
RCA = 96°). (B) Superhydrophobic coating composed of 1:1 blend of PCL:PGC-C18 
(ACA = 170°, RCA = 146°).  
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Figure 5.4 Strain-dependent release of model drug (hydrophilic green dye) from a 
tension-responsive, superhydrophobic drug delivery system, showing cumulative dye 
release as a function of tensile strain. Error bars denote +SD for triplicate samples. 
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Figure 5.5 Contrast-enhanced microcomputed tomography (µCT) imaging 
assessment of tension-responsive superhydrophobic coatings. (A) Specimen cross-section 
before applying tension along the x-axis, showing minimal wetting. (B) Specimen cross-
section after applied tension (ε = 1.0), showing a high degree of water absorption (blue). 
Arrowheads define the boundary of the device (z-axis, device ‘thickness’). 
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Figure 5.6 Crack initiation and propagation photographs highlighting crack 
development in the superhydrophobic, water impermeable barrier coating as strain (ε) is 
sequentially increased to: (A) 0.3, (B) 0.46, (C) 0.62;  along the x-axis. 
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Figure 5.7 Analysis of fracture patterns within superhydrophobic microparticle 
coatings. (A) Number of cracks and total crack area as a function of increasing strain. (B) 
Average crack area as a function of increasing strain.  
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Figure 5.8 Photographs of electrosprayed sputter-coated PDMS “compact tension” 
specimens, tested in accordance with ASTM Standard D 5049-99. (A) Specimen before 
tension, with notch indicated. (B) Specimen after applied tension, with fracture occurring 
on the notched plane. 
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Figure 5.9 Tension-responsive release of cisplatin. (A) Cumulative release of 
cisplatin under varying applied strains. (B) Corresponding strain-dependent dose 
response of in vitro cisplatin delivery to esophageal cancer (OE33) cells after 30 minutes. 
Cisplatin concentrations were measured using flameless atomic absorption 
spectrophotometry, and cell viability was determined by MTS assay.  
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Figure 5.10 Tension-responsive release of SN-38. (A) Cumulative release of SN-38 
under varying applied strains. (B) Corresponding strain-dependent dose response of in 
vitro SN-38 delivery to human esophageal cancer (OE33) cells after 15 minutes. SN-38 
release was quantified using fluorescence spectrophotometry and cell viability was 
determined by MTS assay. 
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CHAPTER 6:  Polymer Nanoparticle-Film Composites as Non-Migrating, Multi-
Modality Breast Tissue Biopsy Markers 
 
6.1 Introduction 
 
Minimally invasive, image-guided core needle biopsy of breast lesions is the 
preferred method for tissue diagnosis of palpable abnormalities and suspicious imaging 
findings observed during breast screening and physical examination. It is now standard of 
care to mark the biopsy site with a biopsy marker272 for two primary purposes.273-275 First, 
in the case of confirmed malignancy, it is crucial to properly mark the area of concern for 
future reference and targeting, since the surrounding tissue features may change due to 
tissue removal and remodeling/healing around the biopsy site. Second, in the case of 
benign lesions, markers avoid unnecessary repeat biopsies by alerting future physicians to 
this initial mass or cluster of calcifications. 
Biopsy marker visibility under magnetic resonance imaging (MRI), ultrasound 
(US), and mammography is critical, as in recent years MRI and US have played an 
increasingly important role in medical imaging evaluation of breast lesions and are 
particularly useful for image-guided biopsies in breast screening programs.276-279 
Commonly used biopsy markers typically rely on small parts of titanium or stainless steel 
for visualization under mammography, and their artifacts on MRI can sometimes serve as 
a means of visualization. While titanium markers elicit small MRI susceptibility artifacts 
that may serve as biopsy site identifiers if sufficient in size, artifacts caused by stainless 
steel markers may be unacceptably large, potentially obscuring pathologically relevant 
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areas surrounding the biopsy site.280-282 The latter case is likely to become increasingly 
problematic as higher field-strength magnets are introduced into more clinical 
institutions.283-285 Furthermore, US visibility of these metal markers is limited, and newer 
marker designs have incorporated bioresorbable polymer beads containing entrapped CO2 
bubbles286 or collagen plugs287 to improve US contrast. However, these approaches only 
maintain US visibility for a limited duration (~4-8 weeks),286 making the development 
and use of markers with permanent US visibility of significant interest. 
Another critical requirement is that biopsy markers remain at their intended 
location without migrating. Several clinical reports and reviews286,288-293 describe marker 
migration, which can be categorized as fast or slow migration, or a combination thereof. 
Fast marker migration generally occurs within seconds or minutes after its deployment, 
while slow migration is typically considered dislocations occurring days, weeks, or 
months after deployment. Among others,290 one common source of fast migration is the 
accordion effect, which occurs during stereotactic biopsy and results in marker migration 
along the line of decompression after placement and subsequent release of compression. 
Procedural error is usually ruled out in these fast migration cases, as it is standard 
practice to confirm proper marker placement immediately after deployment using 
stereotactic imaging with the breast still under compression.272 The use of dense metallic 
markers in fatty breast tissue is a potential source of slow migration due to the difference 
in densities between the marker and tissue. Recently conducted quality assurance studies 
at the Boston University Medical Center’s Breast Imaging Center analyzed 275 vacuum-
assisted, stereotactic core breast biopsies and found 12.5% of markers deployed in 
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uncomplicated stereotactic procedures experienced dislocations between 1 and 6 cm, with 
an average fast migration distance of 2.4 ± 1.25 cm—measured as the maximal 2D 
distance from marker to biopsy cavity center.294 Stereotactic images acquired 
immediately after biopsy with the breast still under compression confirmed proper 
marker placement, while mammograms performed later that day (after breast 
decompression) in the craniocaudal (CC) and mediolateral oblique (MLO) views assessed 
fast migration. Figure 6.1 shows one such case of a 4-cm dislocation due to the 
accordion effect occurring in a 68-year old patient. 
Consequently, there is an opportunity to improve patient care by developing a 
marker that provides clear visibility under the three commonly used imaging modalities 
for breast cancer diagnosis (mammography, US, MRI) and prevents fast and slow 
migration upon deployment at the biopsy site. Herein a new multimodality biopsy marker 
is described, which undergoes a change in shape/conformation upon deployment to 
minimize fast and slow migration. 
 
6.2 Results 
 
6.2.1 Device Fabrication & Cytocompatibility Assay 
Prototype biopsy markers (Figure 6.2) were fabricated from low-density 
polyethylene (LDPE), 20-nm iron oxide nanoparticles, and a thin superelastic Nitinol 
wire using a melt-press or a solvent cast technique. The materials and their corresponding 
function with regards to device performance are described in Table 6.1. The 
nanoparticles could be either concentrated in one area or dispersed throughout the film. 
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The prepared markers were flexible and could be rolled into an 11-gauge (G) introducer 
needle for subsequent deployment and evaluation in fast and slow migration assays. The 
melt-press method was used for all subsequent imaging and migration studies. In vitro 
cytotoxicity studies using NIH/3T3 (mouse fibroblast) cells showed no evidence of 
toxicity with results similar to untreated controls. 
 
6.2.2 Multimodality Imaging 
Markers were clearly visualized by imaging technologists and physicians (rated as 
“excellent visibility, or 5 on a scale of 1, not visible, to 5, excellent visibility) (Table 6.2) 
using clinical imaging instruments of the three modalities currently applied in breast 
imaging (mammogram, US, and MRI) in ex vivo chicken breast, bovine brisket, bovine 
liver, and biopsy training phantoms. Contrast-to-Noise values, computed to quantify 
marker visibility under ultrasound, MRI, and mammography, were 10.1 ± 2.1, 16.8 ± 9.8, 
and 16.2 ± 6.5, respectively (Table 6.3). Figure 6.3A is an US image of a biopsy marker 
implanted in a chicken breast phantom, seen as a thick, bright hyperechogenic region 
(corresponding to the polyethylene) in the image (white arrow), with thinner lines below 
representing reverberation artifacts. MRI visibility of the biopsy marker (loaded with 50 
µg iron oxide nanoparticles) (Figure 6.3B) was a consequence of the susceptibility 
artifact from iron oxide (black arrow), and the Nitinol wire was visible under 
mammography (white arrow, Figure 6.3C). The markers were readily visible in 
mammograms of biopsy marker-loaded tissue phantoms (silicone training phantom, 
bovine liver, brisket, and chicken breast), which were selected to represent the range of 
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fat content and density found in human tissue. Evidence of mammographic visibility of 
markers loaded in these additional phantoms is provided in Figure 6.4. 
 
6.2.3 Tunable MRI Visibility of Breast Tissue Biopsy Markers 
Detection via MRI imaging arises from susceptibility artifact volumes (Figure 
6.5) obtained using bilateral imaging in the sagittal view with SENSE (BLISS) and T2-
weighted turbo-spin-echo (TSE) sequences. A strong correlation was observed between 
artifact size and iron oxide nanoparticle loadings above 25 µg (Figure 6.6A). Similar 
artifact volumes were obtained with both imaging sequences, with slightly greater 
variability using BLISS. Regression analysis of artifact size as a function of nanoparticle 
loading for both BLISS and T2-weighted TSE data indicated high linearity (R
2
BLISS = 
0.994, R2TSE = 0.998; Figure 6.6B) and similar slope values. 
 
6.2.4 Deployment, Resistance to Fast & Slow Migration 
Deployment of prototype biopsy markers in tissue phantoms was accomplished 
using standard 11G clinical introducers, causing the markers to unfold and change shape. 
This shape change upon deployment geometrically constrained markers from fast 
migration, which was supported by mammographic imaging that showed the Nitinol wire 
extending to 4 mm in length—larger than the diameter of the introducer needle (~2 mm) 
(Figure 6.7). The markers also remained at their deployment site without experiencing 
substantial fast migration caused by the accordion effect, compared to conventional 
markers (1.4 ± 0.33 mm and 6.1 ± 0.82 mm, respectively) (Figure 6.8A). Slow migration 
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was also observed in accelerated long-term studies, with the prototype migrating 4.6 ± 
0.8 mm versus 26.0 ± 14.1 mm for the conventional marker (Figure 6.8B and Figure 
6.9). 
 
6.3 Discussion 
 
Biopsy marker fabrication was successfully accomplished using the melt-press 
and solvent-casting techniques. The ability to process these materials using melt-
processing allows for scalable manufacturing, as the dispersion of solid inorganic 
nanoparticles into polymer matrices is an established technique in the rubber, plastics, 
and opto-electronics processing industries to improve the strength, stability, color 
retention, or electronic properties of these materials.295,296 Here, solid iron oxide 
nanoparticles were embedded within the polymer film to provide MRI contrast.297 
Permanent implantable medical device materials consisting of polyethylene (or 
polyethylene-nanoparticle composites)298 are known to be safe299 and are in routine 
clinical use.300 Iron oxide nanoparticles are also generally considered safe and are FDA-
approved for treatment of anemic patients with chronic kidney disease (via i.v. 
administration), as well as for use as MRI contrast agents.301-306 Preliminary in vitro 
cytotoxicity studies reported here using NIH/3T3 (mouse fibroblast) cells co-incubated 
with prototype markers showed no toxicity in comparison to untreated controls. Given 
these in vitro results and the current clinical use of the marker’s component materials, 
these inert, non-degradable biopsy markers are expected to be biocompatible and unlikely 
to elicit adverse reactions. Complete safety and biocompatibility studies are planned to 
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determine the in vivo biological response to these devices prior to any clinical use. 
Multimodality breast imaging, including the use of breast MRI, is increasing in 
the United States and Europe,307-311 and is tremendously important for early lesion 
detection, diagnosis, and treatment planning. However, the orthogonal imaging platforms 
of mammography, US, and MRI lose their synergistic value when cross-modality 
visibility of the biopsy marker is lacking or only temporary. Some conventional markers 
(e.g., SenoMark UltraCor™ MRI) lack permanent US visibility because the material of 
the marker responsible for US signal degrades. One potential solution is to construct the 
bulk of the biopsy marker out of non-biodegradable polyethylene, which is visible by US. 
Polyethylene implants are routinely used in long-term hip replacement surgery, and their 
slow breakdown is largely due to high-friction, high-load wear, which is absent in the 
breast and therefore not expected to reduce the biopsy marker’s lifetime. Constructing 
biopsy markers from polyethylene, loaded with iron oxide nanoparticles and a Nitinol 
wire, permits clear visualization under all three modalities applied in breast imaging 
(mammogram, US, and MRI). 
Biopsy markers with tunable MRI visibility are particularly attractive, especially 
with regards to optimal use on available scanners with different field strengths (1.5T and 
3T platforms), and can be accomplished using iron oxide nanoparticles embedded into 
the polyethylene matrix of the biopsy marker. The small local magnetic field generated 
by these nanoparticles elicits observable susceptibility artifacts whose size depends on 
the amount present, with 25 µg per marker considered the threshold quantity—amounting 
to approximately 1000-fold less than that given in a standard intravenous injection to 
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anemic patients with chronic kidney disease.305,306 
For a marker to fulfill its intended purpose, it also must not migrate from its target 
location. However, migration of markers is described in case reports and reviews and 
represents a significant clinical shortcoming in optimal patient care. The two major 
causes of fast migration involve either incomplete marker detachment from the introducer 
(causing it to be pulled back through the needle track after introducer withdrawal), or by 
the release of breast compression during stereotactic image-guided core biopsies, called 
the “accordion effect”. The latter is one of the most prevalent causes of fast migration 
described in the literature. A marker that changes shape or configuration upon exiting the 
introducer, which subsequently occupies a greater area within the cavity than the 
dimensions of the needle track, may help overcome fast migration. Evaluation of 
prototype marker migration within ex vivo bovine tissue (i.e., brisket) phantoms indicated 
a resistance to fast migration, with prototype markers migrating about 6× less than 
conventional markers. 
Slow migration, on the other hand, occurs as a consequence of a density mismatch 
between the tissue and marker, with the dense marker moving through the less dense 
breast tissue, or due to tissue growth and/or remodeling at the deployment site. 
Constructing the bulk of biopsy site markers from polyethylene, which has a density of 
~0.92 g/cm3, more closely resembles that of soft tissue (~0.90 – 1.1 g/cm3 for fatty and 
muscular tissue, respectively), especially when compared to titanium or stainless steel 
markers (2+ g/cm3). Accordingly, accelerated slow migration studies showed differences 
in migration distance between prototype and conventional markers (4.6 mm versus 26 
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mm, respectively—or 5× less dislocation distance). The change in marker shape and 
similar density to breast tissue are the likely factors responsible for reducing slow 
migration, and further experiments are planned for evaluating migration in vivo. 
Alternative biopsy marker designs are being developed and commercialized by others to 
also address migration, such as the O-Twist MarkerTM, Tumark® Professional, and 
SecurMark® markers. However, these devices either lack additional components for 
improving US and MR visibility312,313 or were recently reported in one study to undergo 
fast migration > 1 cm in 10-20% of stereotactic breast biopsy procedures.294 
With regards to marker fabrication and migration experiments, there are a few 
limitations to the present study. First, the long-term residence of iron oxide nanoparticles 
embedded within the film has not been tested. However, negligible nanoparticle leaching 
is anticipated due to the hydrophobic, nonporous nature of the film and the hydrophobic 
coatings found on the nanoparticles themselves, which prevent their aqueous dissolution. 
This hypothesis can be tested in future in vivo studies using an iron-specific stain 
(Prussian Blue) during histological evaluation around the implant site. Second, complete 
in vivo biocompatibility studies are required, in accordance with ISO 10993 and FDA 
guidelines, to translate this technology to a clinical setting. Third, the studies herein were 
limited to assessing slow marker migration through simulated fatty breast tissue using 
centrifugation and did not assess for other potential sources of migration, such as the 
repetitive up-and-down motion of the breast during physical exertion. These conditions 
will ultimately be evaluated in human breast tissue—both ex vivo and in a clinical 
setting—which will best assess the factors responsible for migration in patients. 
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6.4 Conclusion 
In conclusion, a novel migration-resistant biopsy marker was fabricated from 
polyethylene, iron oxide nanoparticles, and a superelastic Nitinol wire to provide 
permanent visibility under US, MRI, and mammography, respectively. Importantly, MRI 
visibility was controlled by varying the nanoparticle content within the films. The marker 
was constructed from non-degradable materials, with polyethylene being the major 
component. These markers could be deployed using an 11G clinical introducer; and once 
deployed, they unfolded to give geometrically constrained structures. These markers did 
not show appreciable fast migration, as tested using ex vivo bovine tissue phantoms and 
mammographic follow-up imaging, unlike a conventional marker, and similarly exhibited 
substantially reduced slow migration. The factors responsible for minimizing the fast and 
slow migration included: 1) the flexible polyethylene film and Nitinol wire, which work 
in concert to unfold the marker as it leaves the introducer to secure it within the biopsy 
cavity; 2) the unfolded marker being larger than the introducer needle or track; and 3) the 
density of the marker more closely matching soft tissue. Use of a multimodal, non-
migrating biopsy marker will improve accurate diagnosis and assessment of breast 
lesions and consequently facilitate more accurate multimodal imaging-based treatment 
for breast cancer patients. 
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6.5 Materials & Methods 
 
6.5.1 Biopsy Marker Fabrication 
Biopsy marker prototypes were constructed with a short, 0.75-cm piece of 
superelastic Nitinol wire (0.007” diameter, Small Parts, Inc.), and 20-nm oleic acid-
coated iron oxide nanoparticles (Ocean Nanotech, Inc.) sandwiched between two 1cm2 
squares of low-density polyethylene (LDPE) films (Poly-America Corporation). LDPE 
sheeting was cut into 1-cm2 squares, and each square was indented slightly in the center 
to hold 10 µL of nanoparticles dispersed in chloroform. The solvent was evaporated 
overnight to afford the nanoparticles. For studying MRI susceptibility artifact size as a 
function of nanoparticle loading, a stock dispersion of iron oxide nanoparticles was 
prepared at 10 mg/mL in chloroform (Clean Harbors, Inc.), and serially diluted 2-fold to 
yield a range of concentrations (10 mg/mL – 30 µg/mL, total nanoparticle mass of 390 ng 
- 100 µg per film) in the subsequent markers. Next, a superelastic Nitinol wire was placed 
in the center of the film, and a second LDPE film was placed on top of the wire, 
nanoparticle, and first LDPE film. The two LDPE films were then melted together to 
create a single film using a hot metal surface (i.e., a melt-press method). Finally, the 
device was cut to size (0.5 cm x 0.5 cm) prior to subsequent testing and evaluation. 
For demonstrating versatile fabrication techniques, additional prototype markers 
were constructed using a solvent casting method: In this process, LDPE (15 wt%) and 
iron oxide nanoparticles (5 mg) were dissolved in toluene at 80 °C, poured into a pre-
warmed glass dish and dried in a 100 °C oven under ambient pressure for 2 hours. A 
vacuum was applied to the oven to remove trace solvent for an additional 2 hours. While 
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both fabrication methods produced markers visible under mammography, MRI, and 
ultrasound, the melt-press method was used to construct biopsy markers for all 
subsequent imaging and migration experiments. Prototype markers were cut to their final 
size (0.5 cm x 0.5 cm squares, 300 µm thick) and had a mass of ~15 mg. For comparison, 
a conventional breast tissue biopsy marker, SecurMarkTM (Hologic, Inc.), consists of a 
metal cylinder (0.2 cm in length and 0.1 cm in diameter) entrapped within a resorbable 
mesh that is 1.5 cm long and ~0.15 cm in diameter (total marker mass = 9 mg). 
 
6.5.2 Cytocompatibility Assay 
A cytotoxicity assay, using NIH/3T3 mouse fibroblast cells, was performed by 
co-incubating the cells with finished biopsy markers, and viability was assessed using a 
MTS colorimetric assay. Cells were seeded in a 12-well tissue culture plates at a density 
of 4 x 104 cells/well and allowed to adhere/incubate overnight, and then co-incubated 
with prototype markers in transwell plates for an additional 24 hours. 
 
6.5.3 Biopsy Marker Imaging 
All imaging experiments were performed on clinical instruments. Mammograms were 
performed on bovine liver (700 cm3), bovine brisket (550 cm3), chicken breast (250 cm3), 
agar gel (400 cm3, Sigma-Aldrich), and a stereotactic breast biopsy training phantom 
(530 cm3, CIRS, Inc.) using a Hologic Digital Selenia mammography unit. These tissue 
phantoms were selected to simulate the variability in human breast tissue, which can 
range from predominantly fatty tissue (brisket, liver and breast biopsy training phantom) 
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to dense or hydrated tissue (chicken breast and agar gel, respectively). US imaging was 
performed on these phantoms using a Philips iU22 US system with a 17.5 MHz linear 
transducer. MRI imaging was performed using T2-weighted turbo spin echo (TSE) and 
T1-weighted gradient echo (bilateral breast imaging in the sagittal view with SENSE, 
‘BLISS’) sequences using a Philips Achieva 1.5T XR scanner with a 16ch head coil. MR 
imaging parameters were as follows: T2-weighted TSE: Repetition time/echo time: 
2,500/120, echo train length: 25, flip angle 90°, 25-cm field of view, 480 x 480 matrix, 
section thickness: 1.5 mm, 1.5 mm gap, 3 averages, acquisition time 2:35, and no phase 
wrap; BLISS (T1-weighted radial gradient echo): Repetition time/echo time: 7.2/3.5, flip 
angle 12°, 25-cm field of view, 384 x 384 matrix, section thickness: 3.0 mm, no gap, 6 
averages, acquisition time 1:50, and no phase wrap. A total of ten images (4 ultrasound in 
chicken breast, 4 MR images in chicken and bovine brisket, and 2 mammograms in 
bovine brisket and chicken breast) were randomly selected and evaluated for marker 
visibility by four independent, anonymous observers (consisting of two radiologists and 
two mammography imaging technologists). Visibility was assessed on a scale of 1-5: (1) 
not at all visualized, (2) not sufficiently visible/not definitely identifiable, (3) adequately 
visualized/identified but not well seen, (4) well visualized/clearly identified; and (5) 
excellent visibility/very well delineated. 
 Contrast-to-Noise ratios (CNR) for quantifying marker visibility under each 
modality were calculated using ImageJ (National Institutes of Health) by selecting 
regions of interest (ROIs) corresponding to tissue, measuring the average pixel intensity 
of each, and comparing these values to those of a ROI drawn around the marker itself. 
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The equation: 
CNR = |SA – SB|/o ; 
where SA is the signal intensity of the marker, SB is the intensity of the surrounding tissue, 
and o is the standard deviation of the phantom noise, was used for reporting marker 
visibility in the surrounding tissue. 
 
6.5.4 MRI Image Analysis & Tuning Artifact Size 
For studying artifact signal as a function of iron oxide nanoparticle concentration, 
biopsy markers with different nanoparticle loadings were prepared and loaded into a 1% 
agar phantom such that all the biopsy markers were oriented in the same direction and 
submerged 2 mm under the gel surface. Markers were prepared in triplicate and 
accordingly placed into three separate phantoms; all phantoms were imaged at the same 
time using a head coil and T2-TSE and BLISS sequences. 
The complete DICOM image set was assessed using Analyze (Mayo Clinic). 
Briefly, an object map was drawn around each biopsy marker in an appropriate slice, and 
a threshold voxel intensity (reference intensity) was specified to delineate accurately and 
reproducibly the size of the signal void/artifact caused by the marker. All voxels, with 
signal intensities equal and below this reference “dark voxel” intensity were considered 
part of the artifact. The dark voxels were summed and multiplied by the voxel 
dimensions (1.5 mm x 0.5 mm x 0.5 mm) to calculate the artifact size in cubic 
millimeters. For the T2-weighted TSE analysis, bright voxels, also due to the artifact, 
were prominent and also summed and included in the analysis. 
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6.5.5 Deployment, Fast & Slow Migration Studies 
Ex vivo bovine brisket phantoms were used for assessing fast and slow migration 
to mimic the properties of a fatty breast, as fatty breast consistency has been suggested as 
a major contributing factor to marker migration.290 Biopsy markers were rolled into 
cylindrical shapes and loaded into the empty cannulas of biopsy marker introducers (11G 
CeleroMark™, Hologic, Inc.). Migration due to the accordion effect was assessed by 
building a simulated stereotactic biopsy table out of a modified acrylic box that 
permitted: 1) vacuum-assisted core biopsy and subsequent clip placement, with the 
needle track along the line of compression; 2) post-deployment imaging by 
mammography before the release of compression; and 3) recoil of tissue upon release of 
compression. Imaging was performed after marker deployment, needle withdrawal, and 
release of compression (n = 2). SecurMark™ biopsy markers were also deployed in 
phantoms for comparison (n = 2). To approximate/accelerate slow migration, phantoms 
were subjected to centrifugation (2000 rpm, 16 hours, room temperature). Centrifugation 
was selected to ensure migration would reproducibly occur within a reasonable amount of 
time (16 hours) without causing tissue spoilage, and a speed of 2000 rpm minimized 
tissue deformation that would have otherwise occurred at higher speeds. Centrifugation 
was not performed under refrigeration conditions (which would have allowed for longer 
centrifugation times) because this condition would have artificially stiffened the tissue. 
After centrifugation, the phantom tissues were imaged by mammography in the 
craniocaudal (CC) and true lateral (90°) positions, simulating a real post-marker 
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mammogram. The distance from biopsy marker to cavity center was measured to assess 
the relative extent of dislocation in both fast and slow migration studies. 
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Table 6.1 Components of a new polymer-nanoparticle composite biopsy marker. 
Material/Component Function 
Polyethylene film Provides flexibility and US visibility 
Iron oxide nanoparticles Tunable MRI contrast agent 
Superelastic Nitinol wire 
Added elasticity to polymer film, visible 
under mammography 
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Table 6.2 Scoring criteria for biopsy marker visibility survey (x = radiologist, y = 
technologist). 
 
 
 
KEY 
 
 
 
 
 
 
  
 
Ultrasound Image No. MRI Image No. 
Mammogram 
Image No. 
Score 1 2 3 4 1 2 3 4 1 2 
1           
2           
3           
4           
5 xxyy xxyy xxyy xxyy xxyy xxyy xxyy xxyy xxyy xxyy 
   
   
Score Description 
1 Not at all visualized 
2 Not sufficiently visible 
3 Adequately visualized 
4 Well visualized 
5 Excellent visibility 
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Table 6.3 Contrast-to-Noise ratios for biopsy markers deployed in tissue phantoms. 
Imaging Modality Contrast-to-Noise Ratio 
Ultrasound 10.1 ± 2.1 
MRI 16.8 ± 9.8 
Mammography 16.2 ± 6.5 
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Figure 6.1 Clinical example of accordion effect after stereotactic biopsy procedure. 
(A) Diagnostic mammogram of 68 year-old patient with suspicious calcifications circled 
in yellow (inset: subsequent stereotactic biopsy shows marker placement within the 
biopsy cavity. (B) Lateral migration of marker (arrowhead) 4 cm from biopsy site 
(arrow). (C) Follow-up at 6 months shows marker remaining at distant site. 
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Figure 6.2 Design of the non-migrating, multimodality imaging breast biopsy marker. 
(A) Cross-sectional diagram of the marker consisting of a polymer-nanoparticle 
composite film with an encased superelastic Nitinol wire. The polymer film is confined 
within the introducer, with the wire and viscoelastic film exerting pressure on the walls of 
the introducer (shown by green arrows). (B) Photograph of a prototype biopsy marker 
fabricated from a cast solution of dissolved iron oxide nanoparticles and LDPE at 80 °C. 
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Figure 6.3 Multimodal visibility of breast biopsy site markers loaded in chicken 
breast phantoms using (A) ultrasound, (B) MRI, and (C) mammography.  
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Figure 6.4 Mammograms of prototype markers in tissue phantoms representing 
varying fat content and density found in human breast tissue. From left to right: fatty 
tissue phantom (stereotactic breast biopsy training phantom; the bright circle is an 
artificial lesion used for training purposes); predominantly fatty/fibroglandular tissue 
from a bovine liver phantom; heterogeneous fatty tissue from a brisket phantom; 
dense/hydrated tissue from chicken breast. 
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Figure 6.5 MRI of 1% agar gel phantom with corresponding markers (BLISS 
sequence) where the highest nanoparticle loading is in the top left, and the loading 
decreases from top left to bottom left (a marker with no nanoparticles) in the MR image. 
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Figure 6.6 Tunable MRI visibility. (A) Artifact volume as a function of iron oxide 
nanoparticle (NP) loading for T1-weighted gradient echo (BLISS) and T2-weighted TSE. 
(B) Linear regression of susceptibility artifact size as a function of iron oxide 
nanoparticle loading in polymer-nanoparticle biopsy marker composites. Error bars 
denote ± SD (n = 3).  
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Figure 6.7 Demonstration of breast tissue marker deployment within biopsy cavity 
(not to scale). The marker film (shown in brown) is confined to a rolled-up cylinder 
inside a breast tissue marker introducer cannula. Deployment causes the superelastic 
Nitinol wire to resume its shape and partially unroll to occupy the biopsy cavity (outlined 
in yellow). 
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Figure 6.8 Fast and slow migration study. (A) Fast migration due to the accordion 
effect for prototype and conventional breast biopsy site markers. (B) Simulated slow 
migration for prototype and conventional markers.  
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Figure 6.9 Mammographic images showing slow migration from the biopsy cavity 
for (A) prototype and (B) conventional biopsy markers. 
 
 
 
194 
CHAPTER 7:  Summary 
 
 
The field of stimuli-responsive drug delivery has tremendous potential in 
delivering therapeutic agents to the specific cells and tissues requiring them—and in an 
on-demand fashion. These approaches attempt to overcome the systemic toxicity issues 
often faced with harsh chemotherapeutics or widely-acting biologics, and achieve greater 
clinical outcomes by using stimuli to provide targeting capabilities. Despite the mature 
field of pH-, temperature-, and electro-responsive drug delivery materials, stimuli 
responsive drug delivery using mechanoresponsive materials that respond to shear, 
compression, and tension is still a nascent technology. This is surprising, considering the 
routine forces encountered in the human body and the intuitive on-demand triggering 
abilities of mechanical force. This dissertation has explored three-dimensional networks 
and polymer-metal composites as mechanoresponsive biomaterials by using mechanical 
force to either trigger the release of entrapped agents or change the conformation of 
implants. 
The work covered in this dissertation first described the current attempts by others 
to develop mechanoresponsive drug delivery materials. Chapter 1 highlighted important 
breakthroughs in this field and identified the potential of developing hydrogels for the 
mechanoresponsive delivery of biologics such as proteins and growth factors. 
Furthermore, Chapter 1 described the field of mechanoresponsive wetting (i.e., triggering 
the rapid wetting of an otherwise non-wetting, or superhydrophobic, material). 
Considering the recent development of superhydrophobic materials for drug delivery 
 
 
 
195 
applications, the prospect of combining such a mechanoresponsive wetting strategy with 
a superhydrophobic drug delivery system emerged. 
In Chapter 2, shear-thinning, self-healing low molecular weight hydrogels 
composed of glycosyl-nucleoside-lipids were synthesized for shear-responsive delivery 
of biopharmaceuticals, such as anti-human tumor necrosis factor alpha. This strategy 
represents the first known report of a low molecular weight hydrogel achieving shear-
responsive delivery of an active biologic by disrupting its three-dimensional nanofibrous 
network. While hydrogels are particularly useful for biomedicine, their high water 
content generally precludes their use as sustained release systems due to rapid diffusion, 
which set the stage for research into other systems with sustained release capabilities. 
In contrast to water-loving (‘hydrophilic’) drug delivery materials, hydrophobic 
materials were developed for sustaining the release of chemotherapy to lung cancer 
resection margins. Chapter 3 focused on the development of cisplatin-loaded 
superhydrophobic nanofiber meshes, which were fabricated by the electrospinning 
process using the biodegradable, biocompatible polymers polycaprolactone and 
poly(caprolactone-co-glycerol monostearate). This system was designed to account for 
the dynamic properties of the lung using flexible meshes, which were compliant, 
amenable to stapling/suturing, and exhibited an extraordinary resistance to wetting, which 
sustained the release of cisplatin in a linear fashion over 90 days in vitro, and 
significantly delayed tumor recurrence in an in vivo murine lung cancer resection model. 
To generalize the strategy of polymer chemistry and electrospinning to achieve 
superhydrophobic materials, a family of polylactide-based poly(ester carbonate)s were 
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synthesized and characterized, and were reported in Chapter 4. Those efforts discovered a 
general approach to fabricating new biomedical materials with similar non-wetting 
capabilities. Overall, the disciplines of polymer chemistry and electrospinning for 
achieving drug delivery systems laid the groundwork for future developments in 
mechanoresponsive drug delivery by first extensively studying their release kinetics in 
the absence of stress. Through those studies it became clear that the superhydrophobicity 
and exclusion of water from within the bulk material prevented burst release of 
encapsulated agents. 
In Chapter 5, the ability to rapidly trigger drug release from superhydrophobic 
materials using tension was explored using a multilayered drug delivery device consisting 
of a water-absorbent core flanked by two superhydrophobic microparticle coatings. 
Applied strain initiates coating fracture to cause core hydration and subsequent drug 
release, with rates dependent on strain magnitude. These studies have provided the basis 
for developing next-generation devices that incorporate superhydrophobic coatings to 
rapidly and locally deliver therapeutic agents to specific tissue sites using tension as the 
release stimulus. 
Finally, macroscopic, shape-changing polymer-composite materials were 
developed in Chapter 6 improve the current functionality of breast biopsy markers using 
a flexible polyethylene matrix embedded with superparamagnetic iron oxide 
nanoparticles and a superelastic Nitinol wire. These three components provided visibility 
under the three commonly used imaging modalities for breast imaging (ultrasound, MRI, 
and mammography). Furthermore, the Nitinol wire’s elasticity caused a shape change 
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after deployment in the biopsy site, which provided a means to prevent marker migration 
from its intended site—a current clinical problem experienced in minimally-invasive 
breast biopsy procedures. The use of a non-migrating marker will help improve treatment 
planning procedures, facilitate diagnosis, and eliminate confusion associated with biopsy 
markers dislocating over days, weeks, or months—or from a lack/loss of visibility under 
ultrasound or MRI. 
In summary, this dissertation explored mechanoresponsive materials, ranging 
from the nano- to macroscopic scale, for applications in drug delivery and biomedical 
devices. These studies add to the nascent field of mechanoresponsive biomedical 
materials and the arsenal of drug delivery techniques required to combat cancer and other 
medical ailments. 
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